



Published in final edited form as:

*Biosens Bioelectron.* 2016 February 15; 76: 113–130. doi:10.1016/j.bios.2015.07.031.

## Glyconanomaterials for Biosensing Applications

Nanjing Hao<sup>a</sup>, Kitjanit Neranon<sup>b</sup>, Olof Ramström<sup>b</sup>, and Mingdi Yan<sup>a,b</sup>

Olof Ramström: ramstrom@kth.se; Mingdi Yan: mingdi\_yan@uml.edu

<sup>a</sup>Department of Chemistry, University of Massachusetts Lowell, 1 University Avenue, Lowell, MA 01854, USA

<sup>b</sup>Department of Chemistry, KTH - Royal Institute of Technology, Teknikringen 30, S-10044 Stockholm, Sweden

### Abstract

Nanomaterials constitute a class of structures that have unique physiochemical properties and are excellent scaffolds for presenting carbohydrates, important biomolecules that mediate a wide variety of important biological events. The fabrication of carbohydrate-presenting nanomaterials, glyconanomaterials, is of high interest and utility, combining the features of nanoscale objects with biomolecular recognition. The structures can also produce strong multivalent effects, where the nanomaterial scaffold greatly enhances the relatively weak affinities of single carbohydrate ligands to the corresponding receptors, and effectively amplifies the carbohydrate-mediated interactions. Glyconanomaterials are thus an appealing platform for biosensing applications. In this review, we discuss the chemistry for conjugation of carbohydrates to nanomaterials, summarize strategies, and tabulate examples of applying glyconanomaterials in *in vitro* and *in vivo* sensing applications of proteins, microbes, and cells. The limitations and future perspectives of these emerging glyconanomaterials sensing systems are furthermore discussed.

### Keywords

glyconanomaterials; biosensing; carbohydrates; nanotechnology; glycoscience

## 1. Introduction

Carbohydrates are essential in living systems, and collectively have the highest abundance of all biomolecules in nature. They serve for example as energy storage and metabolic intermediates, and carbohydrates conjugated to proteins and lipids mediate molecular recognition, signal transduction, molecular trafficking, cell adhesion, cellular differentiation, inflammation and immune responses (Crocker et al., 2007; Dube and Bertozzi, 2005; Liu and Rabinovich, 2005; Szymanski and Wren, 2005). However, individual carbohydrate-based interactions are often of low affinity, and to overcome this limitation, nature takes

---

Correspondence to: Olof Ramström, ramstrom@kth.se; Mingdi Yan, mingdi\_yan@uml.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

advantages of the multivalency effect, where carbohydrates are clustered together to interact with receptors cooperatively (Lee and Lee, 1995).

Glyconanomaterials, where nanomaterials are used as scaffolds to present carbohydrates, have recently emerged as important structures, showing great potential in many applications including sensing and detection (Adak et al., 2014; Bernardi et al., 2013; Chen et al., 2014; El-Boubbou and Huang, 2011; García et al., 2010; Huang, 2013; Marradi et al., 2013; Reichardt et al., 2013; Wang et al., 2009a, 2010a). Compared to other types of scaffolds, nanomaterials offer a number of attractive features as carbohydrate carriers, such as high specific surface area for accommodating high density ligands, tunable size and shape for modulating ligand density and presentation, nanosized dimensions for exploring the interactions with organisms, and unique optical, electronic, photonic, or magnetic properties for transducing the molecular recognition signals for sensing and detection.

In this review, we begin with a brief discussion on coupling chemistry for glyconanomaterials, including a photoconjugation approach developed in our laboratory. We next summarize the synthesis of gold-, iron oxide-, carbon-, quantum dot- (QD-), silica-, liposome-, polymer-, and dendrimer- based glyconanomaterials, and their in vitro and in vivo applications in sensing and imaging of proteins, microbes, and cells. Finally, we discuss current limitations and future perspectives of this field.

## 2. Carbohydrate conjugation to nanomaterials

Glyconanomaterials are typically prepared following two general conjugation strategies of either non-covalent interactions or covalent bonds, both of which associated with different advantages and drawbacks. In comparison to non-covalent methods, covalent approaches are more frequently used due to the higher stabilities of the covalent adducts. The photocoupling strategy developed in our group, which utilizes suitably functionalized perfluorophenyl azides (PFPA)s for molecular conjugation, provides in this context an efficient alternative.

### 2.1 Non-covalent conjugation

The non-covalent approach relies in conjugation of the carbohydrate structures to the nanomaterials via typical non-covalent interactions, such as charge interactions, hydrogen bonding, van der Waals' forces, or solvophobic effects. This approach can typically be used under relatively mild conditions, and often requires no, or minimal, chemical derivatization of the carbohydrate ligands or the nanomaterial substrates. The interactions can occasionally be very strong, for example based on biotin-streptavidin recognition, but the bond strengths may also be weaker, which could lead to detachment and thereby increased nonspecific interactions with the target. The process can also be non-selective and less controllable compared to covalent linkages. These effects must be taken into account, as they can affect the sensitivity and specificity in sensing applications. For certain systems, however, this approach is highly useful, efficiently applied to large carbohydrate structures like polysaccharides, glycoproteins, and glycolipids.

## 2.2 Covalent conjugation

Mono- and oligosaccharides are commonly conjugated to nanomaterials covalently, either directly or via post-modification coupling reactions. This approach holds the advantage of generating stable linkages and robust surface structures. Typical examples include thiol/disulfide chemisorption on gold and quantum dots, phosphates on iron oxides, and silanes on silica. Of the different covalent systems evaluated, thiol/gold is the most studied and used. This system is well established, relatively stable and reproducible. Post-modification coupling is based on typical conjugation chemistries where complementary functional groups react to form covalent linkages such as amides or triazoles. However, this approach generally requires chemical derivatization of the carbohydrates, the synthesis of which may present considerable challenges, especially for oligosaccharide structures.

In order to achieve high spatial and temporal control over the conjugation process, we developed a photocoupling chemistry that is based on fluorinated aryl azides (Liu and Yan, 2006, 2010; Liu et al., 2010a; Park and Yan, 2013; Wang et al., 2009a, 2010a; Yan and Harnish, 2003; Yan and Ren, 2004). Upon light irradiation and nitrogen extrusion from the aryl azide group, highly reactive singlet nitrene entities are formed, which can insert into CH bonds or add to C=C bonds. This method has been successfully applied to conjugation of carbohydrates (Wang et al., 2009b, 2010b), small molecules (Al-Bataineh et al., 2009), polymers (Gann and Yan, 2008; Wang et al., 2011), carbon materials (Liu et al., 2010a, 2010b), and discrete nanoparticles (Park et al., 2015) to different nanomaterials. Interestingly, this photocoupling approach can be efficiently used for un-derivatized carbohydrates, and is perhaps especially useful for oligosaccharides, which are often difficult to derivatize. Furthermore, the reaction is fast and straightforward, often occurring within minutes at room temperature. Maalouli et al. compared the photocoupling with the classic copper-catalyzed alkyne-azide cycloaddition reaction (CuAAC), and found that carbohydrate surfaces prepared by perfluorophenyl azide photocoupling had higher ligand density and also generated stronger surface plasmon resonance (SPR) signals than those prepared by the click reaction (Maalouli et al., 2013).

## 3. Synthesis of glyconanomaterials

In this section, we focus on several key types of glyconanomaterials, including gold-, iron oxide-, carbon-, quantum dot-, silica-, liposome-, polymer-, and dendrimer-based glyconanomaterials. The specific synthetic approaches to the glyconanomaterials are summarized.

### 3.1 Gold glyconanomaterials

Gold nanoparticles constitute the most extensively employed and studied type of nanomaterials, basically due to the straightforward preparation and surface chemistry, the high stability, and the attractive optoelectronic properties. The particles give rise to localized surface plasmon resonance (LSPR) upon light irradiation, an effect that is highly sensitive to the dielectric environment close to the nanoparticle surface. This phenomenon renders the structures useful for transducing recognition events at the metal surface (Kelly et al., 2003). Colorimetric sensing has thus been established based on the LSPR shift (Aslan et al., 2004;

Saha et al., 2012; Wang and Ma, 2009). When the carbohydrate-receptor interactions cause additional aggregation of gold nanomaterials, larger LSPR shifts will occur, leading to intense color changes that are often visible by the naked eye (Liu et al., 2007). This unique optical property allows for highly sensitive sensing and detection. In addition, the LSPR effect is not subject to blinking, an effect that is associated with quantum dots (QDs), or fluorophore photobleaching of organic structures (Wang et al., 2009a).

Several methods have been employed to synthesize gold glyconanomaterials. A straightforward approach uses reducing sugars as both reducing agents and capping ligands during the formation of gold nanoparticles (Guo and Yan, 2008; Kemp et al., 2009). As the gold precursors become reduced by the carbohydrates to generate gold nanoparticles, hydroxyl/gold interactions lead to a protective carbohydrate layer on the gold nanoparticles. Another in situ method involves the addition of thiol-functionalized carbohydrates to the gold precursors (Chen et al., 2005; De La Fuente et al., 2001; Halkes et al., 2005). The thiol-carbohydrate serves as the capping ligand for gold nanoparticles as they are formed. One drawback of this method is that the particle size could vary significantly depending on the ligand structure as well as the experimental conditions, which are difficult to predict and control (Sundgren and Barchi, 2008). In the ligand exchange method (Chien et al., 2008; Hone et al., 2003; Mahon et al., 2010a; Thygesen et al., 2009), gold nanoparticles are first prepared, and the original ligand is then replaced by thiol-terminated carbohydrates. This protocol could reproducibly generate nanoparticles with predictable sizes. Similarly, in our photocoupling protocol, gold nanoparticles are first subjected to thiol/disulfide-terminated perfluoroaryl azides, and are then subjected to light activation in the presence of carbohydrates (Jayawardena et al., 2013b). With this protocol, a wide range of mono-, oligo-, and polysaccharides have been conjugated to different nanomaterials.

### 3.2 Magnetic glyconanomaterials

Magnetic nanomaterials constitute an important type of nanomaterials that display magnetic properties when subjected to external magnetic fields. Magnetite ( $\text{Fe}_3\text{O}_4$ ) nanoparticles are the most widely used type in sensing applications. Major attributes of  $\text{Fe}_3\text{O}_4$  nanoparticles include: i) straightforward preparation methods yielding particles of 5-30 nm size; ii) excellent biocompatibility, as exemplified by the FDA-approved formulations Feridex for liver imaging (Wang et al., 2001) and Feraheme for iron deficiency anaemia (Lu et al., 2010); iii) high magnetic relaxivities, rendering the materials well suited as contrast agents for in vitro/in vivo magnetic resonance imaging (MRI); and iv) ease of surface functionalization (Gao et al., 2006).

The most direct method to attach carbohydrates to iron oxide nanoparticles is to take advantage of their stabilizing properties during the nanoparticle synthesis (Horak et al., 2007). However, excess carbohydrate is generally required for this approach, and the method is therefore used for easily accessible polysaccharides. An alternative strategy is post-modification of pre-formed nanoparticles by covalent conjugation, for example conjugation of carboxylated carbohydrates to amine-functionalized iron oxide nanoparticles (Shi et al., 2009; Srinivasan and Huang, 2008). Carbohydrates were also conjugated by the CuAAC reaction, where alkyne-derivatized carbohydrates were allowed to react with azide-

functionalized nanoparticles (El-Boubbou et al., 2007, 2010; Lin et al., 2007). This coupling configuration was also reported to give better conjugation efficiency compared to coupling azide-derivatized carbohydrates to alkynylated nanoparticles (Lin et al., 2007). In addition, biotinylated carbohydrates were synthesized and conjugated to streptavidin-coated magnetic nanoparticles (Hatch et al., 2008; Pera et al., 2010). Our photocoupling chemistry can also be applied to make magnetic glyconanomaterials. In this case, iron oxide nanoparticles were treated with phosphate-derivatized PFPAs, to which carbohydrates were conjugated by light activation (Jayawardena et al., 2013a; Liu et al., 2009).

### 3.3 Carbon glyconanomaterials

Carbon nanomaterials include materials ranging from the amorphous carbon to the more recently discovered fullerenes, carbon nanotubes (CNTs) and graphene. The many attractive physical properties of these materials render them highly useful for biosensing. However, these materials are fairly chemically inert, lack reactive functionality, have poor water solubility, and are potentially toxic to cells (Liu et al., 2012). This can however be overcome by carbohydrate functionalization, which improves solubility, biocompatibility and sensing capability.

Because carbon materials are generally non-polar and hydrophobic, non-covalent conjugation approaches often rely on van der Waals' forces,  $\pi$ - $\pi$  stacking, and hydrophobic effects. Derivatization of carbohydrates with lipophilic groups are thus generally required, including lipids (Chen et al., 2004, 2006; Feng et al., 2011; Khiar et al., 2009; Murthy et al., 2012), polyaromatic hydrocarbons (Chen et al., 2011; Sudibya et al., 2009; Wu et al., 2008) or porphyrins (Chen et al., 2012) before treatment with the carbon substrate. Because the carbon glyconanomaterials are not chemically functionalized in these cases, their physical properties can be preserved.

Covalent modification requires either the carbon nanomaterials or the carbohydrates, or both, to be chemically functionalized. Among the carbon nanomaterials, the most homogeneous structures are obtained with fullerenes (Prato, 1997; Wudl, 2002). For graphene and carbon nanotubes, the oxidized materials are most commonly employed, further functionalized with, e.g., amine-derivatized carbohydrate structures (Chen et al., 2013; Gorityala et al., 2010). Pristine graphene and carbon nanotubes are fairly inert, and require the use of reactive species to chemically functionalize them. These include aryl radicals from aryl diazonium salts (Pinson and Podvorica, 2005; Ragoussi et al., 2013), 1,3-dipolar cycloaddition of azomethine ylides to form pyrrolidine (Hong et al., 2010), and cheletropic cycloaddition of nitrenes to form aziridines (Holzinger et al., 2003; Prato et al., 1993). Studies in our group have for example shown that singlet perfluorophenyl nitrenes are especially useful, and highly reactive towards carbon nanomaterials (Park and Yan, 2013). Once the materials are functionalized, functional groups can be introduced which can be readily used for carbohydrate conjugation (Kong et al., 2015).

### 3.4 QD glyconanomaterials

Inorganic quantum dots (QDs) are luminescent semiconductor nanomaterials with attractive physical properties for biosensing. QDs can for example show broad optical excitation and

narrow emission with good quantum yields, and are less susceptible to photobleaching (Alivisatos, 2004; Michalet et al., 2005). Combined with the possibility for multivalent ligand presentation, these characteristics are appealing for sensing and imaging applications.

QD glyconanomaterials can be prepared by capping QDs with carbohydrates through non-covalent interactions, including hydrophobic effects (Osaki et al., 2004) and electrostatic interactions by mixing negatively charged CdSe/ZnS core-shell QDs, capped with carboxymethyl dextran and sulfanylsuccinate groups, with positively charged polylysine (Chen et al., 2003). Covalent approaches include in situ protocols, for example, based on the addition of thiol-functionalized neoglycoconjugates to QD precursor solutions (De la Fuente and Penadés, 2005; Mukhopadhyay et al., 2009). The ligand exchange protocol is similar to the synthesis of gold glyconanomaterials, where the original capping agents can be replaced by thiol-derivatized glycoconjugates (Babu et al., 2007; Chen et al., 2008; Niikura et al., 2007, 2008; Robinson et al., 2005). QD glyconanomaterials have also been prepared by post-modification protocols similar to gold nanoparticles (Higuchi et al., 2008; Kikkeri et al., 2009b; Sandros et al., 2007).

### 3.5 Silica glyconanomaterials

Silica nanomaterials are highly tunable, show high thermal and mechanical stability, good water dispersability, and are easy to functionalize (He et al., 2010). Among different silica formats, mesoporous silica nanomaterials are especially attractive, displaying large pore sizes, high internal volumes and surface areas (Hao et al., 2012, 2014a, 2014b, 2015; Zhou et al., 2015b). Although silica nanomaterials do not inherently possess optical or magnetic properties, these properties can be easily introduced by entrapment of fluorescent dyes or encapsulation of gold/QDs/magnetic nanoparticles, enabling the use of these materials in sensing and imaging (Slowing et al., 2007; Trewyn et al., 2007).

Carbohydrates are typically conjugated to silica nanomaterials through post-modification strategies, including, for example, amide/triazole formation and photocoupling. Examples of the popular CuAAC method include the conjugation of alkyne- or azide-functionalized carbohydrate derivatives (Peng et al., 2007; Zhao et al., 2012), in the latter case resulting in galactose-presenting silica nanoparticles for sensing live hepatic cancer cells. Similarly, solid tumors were targeted with mannose-functionalized mesoporous silica nanoparticles (Gary-Bobo et al., 2011). Our photocoupling method has furthermore been applied to aryl azide-functionalized silica nanoparticles, resulting in glyconanomaterials that were successfully used to sense proteins (Tong et al., 2012; Wang et al., 2011b, 2011c, 2013), and detect bacteria (Jayawardena et al., 2013a, 2015; Wang et al., 2011c) and cancer cells (Jiang et al., 2015).

### 3.6 Liposome/micelle glyconanomaterials

Amphiphilic molecules consisting of hydrophilic carbohydrate head groups and lipophilic hydrocarbon chain segments are generally able to self-assemble in aqueous solutions, some of which forming structures that can ultimately result in vesicular liposome- or micelle-glyconanomaterials depending on the relative lengths, sizes and structures of the involved segments. A large variety of such amphiphilic structures occur naturally (glycolipids) as part



of cell membranes, and serve a variety of different functions in living systems. These and other structures can be prepared from suitable lipophilic entities, such as fatty alcohols, phospholipids, and cholesterol. Following self-assembly, the resulting liposome- or micelle-glyconanomaterials may possess several attractive features, such as high biocompatibility and loading capacity. The structures have furthermore the potential to be efficiently taken up by cells from interactions with the cell membranes, for example owing to fusion with the lipid bilayers of the membranes (Jayaraman et al., 2013). In view of the similarities with glycolipid-presenting cell surfaces, these self-assembled structures show potential for a variety of applications, such as for instance inhibitor development and biosensors.

Many strategies to prepare vesicular liposome- or micelle- glyconanomaterials via self-assembly of amphiphilic structures have been developed (Chabre and Roy, 2010; Jayaraman, 2009; Kiessling et al., 2006; Yan et al., 2005). Principal synthetic approaches to multivalent aggregates include: i) direct self-assembly of appropriate glycosylated amphiphilic molecules, for example based on polyethylene glycol, peptides and/or alkyl linkers with long carbon chains; ii) incorporation of glycosylated amphiphilic molecules with suitable lipid matrices at optimal molar ratios (usually ~5-10%); and iii) functionalization of pre-formed liposomes or micelles with specific carbohydrate structures (Harada et al., 2005). Owing to their relatively straightforward fabrication, liposome- or micelle- based glyconanomaterials have continuously been developed for biomedical applications, and also as tools for biosensing (Assali et al., 2013; Hildebrand et al., 2002; Mahon et al., 2010b). However, a number of challenges need to be addressed for efficient applications in sensing technology. For example, high densities of surface-exposed carbohydrates are difficult to obtain due to the increased risk of vesicular collapse from high concentrations of glycolipid elements. In addition, the orientation and mobility of the carbohydrate moieties can be difficult to control, resulting in reduced carbohydrate surface accessibility for efficient recognition. The structures may furthermore display relatively low stabilities and characterization can be challenging (Jayaraman et al., 2013).

### 3.7 Polymer glyconanomaterials

Some of the limitations met with liposomes can be addressed with polymer- or dendrimer-based glyconanomaterials, i.e. synthetic polymeric/dendrimeric structures carrying core or pendant carbohydrate groups. Thus, the carbohydrate surface densities can in principle be improved, without the risk of severe disruption of the nanoparticulate structure. In addition, since multivalency is an attractive feature for sensing and recognition applications, increased interest in polymers and dendrimers as frameworks for carbohydrate presentation has emerged to improve the interactions between the binding partners. Together with developments in high structural control and biocompatibility, these features offer high potential for the materials to be employed in *in vitro* and *in vivo* sensing and detection.

The glycode of living organisms being highly structure-dependent, the carbohydrate presentation on polymer glyconanomaterials has to be designed with high accuracy where small structural differences may considerably influence target binding. The correct carbohydrate arrangement along the polymeric skeleton is essential in order to accomplish specific recognition and cell communication effects. In principle, two methods can be

adopted for polymer glyconanomaterials synthesis: polymerization with carbohydrate-functionalized monomers, and grafting carbohydrate entities to a polymer backbone. Traditionally, both methods have been carried out in a stochastic manner, resulting in relatively low control over the detailed structure. However, recent developments in controlled (radical) polymerization and solid-phase synthesis have resulted in improved structural fidelity (Yilmaz and Becer, 2013). These efforts, based on modern polymer chemistry in combination with glycoscience, has lead to enhanced understanding of polymer- and dendrimer- based glyconanomaterials, enabling more complex and well-defined architectures of different shapes with high biocompatibilities and affinities. The resulting glyconanomaterials show significant potential for many biological applications, perhaps especially for biosensors (Sunasee and Narain, 2013; Voit and Appelhans, 2010). However, some of their properties may result in limitations, in particular with respect to the structural homogeneity from the polymer synthesis. These effects may be less important for certain applications such as (qualitative) binding and imaging, whereas detailed, quantitative analysis requires highly homogeneous entities.

### 3.8 Dendrimer glyconanomaterials

In contrast to regular polymers, dendrimers are in principle monodisperse macromolecules with well-defined, usually spherical, architectures. The structures are generally of high symmetry, comprise a core scaffold from which branching segments protrude, and are decorated with external functional groups (Astruc et al., 2010; Bosman et al., 1999). In addition, dendrons, i.e. non-spherical, dendritic structures based on single focal points rather than cores with branching points in all directions, can be applied. The dendrimer structures typically contain internal cavities for potential encapsulation, while the external groups define the solubility and chemical performances. Reproducible synthesis of structurally defined entities is therefore accessible, where the structures can be tailored for specific applications. These features have led to the development of complex, yet highly defined, nanoscale carbohydrate-functionalized structures that are more robust than liposomes and which can be further modified (Ashton and Boyd, 1997). High control of ligand densities can also be obtained, owing to efficient synthesis strategies developed. The resulting dendrimer glyconanomaterials have also increasingly found important uses in glycoscience and technology. Many examples of such structures have been reported over last two decades with the main purpose to enhance the binding efficiencies via the multivalency effect.

Three types of dendrimer glyconanomaterials can be distinguished, based on either carbohydrate core structures, pendant carbohydrate entities; or dendrimers built entirely from carbohydrates (Chabre and Roy, 2010; Turnbull et al., 2002), generally synthesized following different divergent (from core and outwards) or convergent (assembly of dendrons) methodologies. Both synthetic methods are based on repeated reaction sequences, where each repetition leads to a new dendritic 'generation'. The divergent approach requires highly efficient and orthogonal chemistry in order to avoid incomplete reactions, but minimizes potential steric complications. The convergent approach, on the other hand, normally yields dendrimer glyconanomaterials of high purity, but may suffer from steric constraints with hindered cores. Dendrimer glyconanomaterials show several advantages as carbohydrate-presenting entities when used in sensing applications. They are generally well-



defined structures that display high chemical stabilities (Boas and Heegaard, 2004), resulting in ease of characterization and evaluation. They permit geometrical control over carbohydrate positioning and density and can be constructed to show high degrees of multivalency (Seebach et al., 1998). These advantages, however, come with a potential drawback of relatively high synthetic efforts, and high production costs.

## 4. Glyconanomaterials for sensing and imaging

For sensing and imaging applications, it is essential that the carbohydrates retain their recognition effects following their conjugation to the nanomaterials. Compared to other biological recognition elements such as antibodies and enzymes, this is less challenging since carbohydrates often display higher stabilities and a wider range of conditions can be applied. Nevertheless, the recognition effects are generally sensitive to the surface presentation, such as ligand density, linker length, surface chemistry, etc. In this section, we overview recent developments in *in vitro/in vivo* sensing and imaging of proteins, microbes, and cells using various glyconanomaterials.

### 4.1 Sensing proteins

Many physiological and pathophysiological processes, such as cell-cell communication, cell adhesion, and cell infection, start with carbohydrates recognizing their cognate binding proteins (Holgersson et al., 2005) (Fig. 1). Understanding the carbohydrate-protein interactions are important, and can generate new leads in developing diagnostic and therapeutic tools (Ernst and Magnani, 2009). Glyconanomaterials can in this context serve as cell mimics, where the recognition event forms the basis for sensing proteins. Studies from our laboratory and others have shown that glyconanomaterials can amplify the binding affinity of carbohydrates to proteins by several orders of magnitude (La Belle et al., 2007; Liu and Yan, 2010; McLean et al., 2005; Wang et al., 2010b, 2011a, 2012a, 2013). This laid a strong foundation for glyconanomaterials in sensing proteins with high sensitivity. Among the proteins tested, concanavalin A (ConA), is ubiquitously applied, especially used for basic studies to develop new sensing systems. In 2001, Kataoka's and Shinohara's groups used gold- and carbon-based glyconanomaterials to study carbohydrate-lectin interactions (Kato et al., 2001; Otsuka et al., 2001). These pioneering studies demonstrated the feasibility of multivalent glyconanomaterials in sensing proteins.

Table 1 summarizes examples when gold-, carbon-, polymer-, and dendrimer-based glyconanomaterials have been applied to sensing lectins. Well-established sensing and imaging techniques have generally been adopted, taking advantages of the unique properties of the proteins, as well as the specific physiochemical properties of the nanomaterials. Figures 2 - 4 are selected examples where glyconanomaterials are used for sensing lectins. The most used transduction and imaging techniques include: 1) UV-Vis spectroscopy/optical microscopy, which relies on the interactions of glyconanomaterials with proteins leading to light absorption/scattering, causing absorbance changes. In addition, oligomeric carbohydrate-binding proteins can interact with multivalent nanoparticles to form aggregates, which can be visualized under the optical microscope or by naked eyes when the agglomerates are large enough. When gold glyconanomaterials are used, interaction/agglomeration also induces a bathochromic shift of the LSPR signal, together with a

decrease in the absorption intensity. 2) Fluorescence spectroscopy/microscopy, which generally takes advantage of fluorescently-labeled proteins and/or glyconanomaterials in a variety of formats. 3) Surface plasmon resonance (SPR). SPR signals are generated upon the interaction of glyconanomaterials with protein-functionalized SPR sensor chips, or vice versa. 4) Dynamic light scattering (DLS). Binding of glyconanomaterials to the proteins increases the hydrodynamic volume of the complex, which can be sensed by DLS. 5) Quartz crystal microbalance (QCM). QCM has proven especially suitable for nanomaterials, owing to their large molecular mass and thereby enhanced signals.

In addition, microarray technologies can be applied to several of the techniques. Multiple ligands are thus typically tethered to solid surfaces, and the parallel binding events with glyconanomaterials monitored. This technique is often preferred when high-throughput screening and rapid binding analysis are required.

#### 4.2 Sensing microbes and cells

Infections by pathogens are often mediated by carbohydrate recognition at cell/virus particle surfaces (Fig. 1) (Finlay and Cossart, 1997). Multivalent lectin-carbohydrate interactions generate strong adhesive forces, and can in this context be used as an effective means of sensing and detecting pathogens. Thus, glyconanomaterials can enable rapid and sensitive detection of pathogen and toxins without time-consuming procedures, such as multiple incubations and washings, or use of nucleic acid amplification/detection. Optical spectroscopy and microscopy (UV-Vis, fluorescence), often combined with cytometry or staining procedures, are the most typically used. SPR and nuclear magnetic resonance technique (MRI) have also been employed. Literature survey of sensing and detection of microbes and cells using glyconanomaterials is tabulated in Table 2. Figure 5 shows an earlier example.

As cellular surfaces are rich in carbohydrates, it is conceivable that glyconanomaterials could serve as cell mimics and interact with different biological entities. Compared to monovalent ligands, multivalent glyconanomaterials bind to cell receptors with greater avidity and specificity, and could lead to fine-tuned sensing combined with modern single particle- and cell detection techniques. The cell status could thus be analyzed more precisely and efficiently, providing in-depth understanding of the interactions between glyconanomaterials and cells. Among different sensing systems, UV-Vis- and fluorescence spectroscopy/microscopy, SPR, and QCM, are for example amenable to quantitative analysis of the binding performance of glyconanomaterials to cell surfaces. Effective nanoproboscopes that can detect, image, and profile microbes and cells will not only aid the understanding of the roles carbohydrates played in disease process, but also the development of new theranostic tools in disease prevention and treatment.

#### 4.3 Tissue- and in vivo- sensing/imaging

Early examples of glyconanomaterials research have focused on carbohydrate-mediated in vitro interactions of proteins, viruses and cells. Recent development has however emerged where carbohydrate ligands are used as targeting entities to direct the nanomaterials to receptor sites in vivo for imaging and tracking specific cells, tissues, and organs based on

the selective carbohydrate/protein-carbohydrate interactions. Similar to sensing and imaging of cells, fluorescence spectroscopic/microscopic techniques are the most commonly adopted. In addition, typical medical imaging methods, such as PET and MRI are also applied, where the glyconanomaterials can serve as contrast agents.

In 2004, an early *in vivo* study was reported to show that glyconanomaterials could behave as anti-adhesion agents against progression of lung metastasis in mice (Rojo et al., 2004) (Fig. 6). Table 3 summarizes examples of detecting and imaging specific disease states in animals using gold-, magnetic-, and QD-based glyconanomaterials. These results highlight the potential of glyconanomaterials for disease diagnostics and eventually as therapeutics to combat infection and cancer. The materials constitute in this sense a particular promising *in vivo* sensing and imaging platform, relatively easily modified to display high biocompatibilities, and avoiding immune responses and nonspecific interactions (García et al., 2015). However, when designing glyconanomaterials as theranostic platforms *in vivo*, clearance of the materials prior to reaching the therapeutic targets, and enzymatic degradation are important factors that need to be taken into consideration and more studies are warranted in this respect.

## 5. Summary and perspective

Clearly, the merge of nanotechnology with glycoscience has resulted in a wide range of important new applications, especially during the past decade. The emerging field of glyconanomaterials has witnessed rapid growth, and already shown strong potential in sensing and detection. A rich variety of glyconanomaterials has furthermore been developed, taking advantage of the different physicochemical properties of specific structures. This has had special impact on the biosensor area, where these materials are now used as useful sensing platforms.

Essential to glyconanomaterials synthesis is the coupling chemistries that can yield efficient conjugation of carbohydrates to nanomaterials. Either non-covalent or covalent approaches have been applied, resulting in functionalized nanomaterials that take advantage of their unique intrinsic properties. The nanomaterials furthermore result in multivalent presentation of the carbohydrate entities at their surfaces, thereby in a sense mimicking certain cells and virus particles. This feature often leads to dramatically increased affinities between the materials and the target receptors, with large impact on the sensing performance of the glyconanomaterials.

Until now, the carbohydrate displays developed have been fairly simple, especially in comparison to the complex carbohydrate-coating (sometimes called the glycocalyx) of different cells. New strategies are thus still needed, particularly regarding the synthesis of glyconanomaterials with high carbohydrate diversity and more sophisticated carbohydrate display, where the ligand density, spatial arrangement, and accessibility can be precisely controlled. This will ultimately result in detailed modulation of the affinities and specificities of the glyconanomaterials to suit different theranostic and biosensing requirements.

Nevertheless, a multitude of successful sensing applications using glyconanoparticles have been demonstrated, many of which mentioned in this review. Many different entities have thus been targeted, both in vitro and in vivo, ranging from discrete carbohydrate-binding proteins, such as lectins, through viruses, bacteria and mammalian cells, to sensing of tissues in live organisms. This development is in rapid progress, leading to sensing and imaging of specific binding partners and eventually to monitor various disease loci and states. Although such biomedical applications are of very high potential, the biodistribution, clearance, and biocompatibility of the glyconanomaterials need to be established for in vivo sensing. This development, together with the progress in glycoscience and glycobiology, will result in the realization of fine-tuned glyconanomaterials for efficient biosensing, diagnostics and therapeutics applications.

## Acknowledgments

This work was in part supported by the National Institutes of Health (R01GM080295 and R21AI109896, to M.Y.), the Royal Institute of Technology, and the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013/under REA grant agreement no 264645.

## References

- Adak AK, Li BY, Lin CC. *Carbohydr Res.* 2014; 405:2–12. [PubMed: 25498197]
- Ahire JH, Chambrier I, Mueller A, Bao YP, Chao YM. *ACS Appl Mater Interfaces.* 2013; 5:7384–7391. [PubMed: 23815685]
- Al-Bataineh, Sa; Luginbuehl, R.; Textor, M.; Yan, M. *Langmuir.* 2009; 25:7432–7437. [PubMed: 19563228]
- Alivisatos P. *Nat Biotechnol.* 2004; 22:47–52. [PubMed: 14704706]
- Ashton P, Boyd S. *Angew Chem Int Ed.* 1997; 36:421–424.
- Aslan K, Zhang J, Lakowicz JR, Geddes CD. *J Fluorosc.* 2004; 14:391–400.
- Assali M, Cid JJ, Fernández I, Khiar N. *Chem Mater.* 2013; 25:4250–4261.
- Astruc D, Boisselier E, Ornelas C. *Chem Rev.* 2010; 110:1857–1959. [PubMed: 20356105]
- Aykaç A, Martos-Maldonado MC, Casas-Solvas JM, Quesada-Soriano I, García-Maroto F, García-Fuentes L, Vargas-Berenguel A. *Langmuir.* 2014; 30:234–242. [PubMed: 24313322]
- Babu P, Sinha S, Surolia A. *Bioconjugate Chem.* 2007; 18:146–151.
- Ban ZH, Bosques CJ, Sasisekharan R. *Organ Biomol Chem.* 2008; 6:4290–4292.
- Baradel N, Fort S, Halila S, Badi N, Lutz JF. *Angew Chem Int Ed.* 2013; 52:2335–2339.
- Barrientos AG, Fuente JMDLa, Jiménez M, Solís D, Cañada FJ, Martín-Lomas M, Penadés S. *Carbohydr Res.* 2009; 344:1474–1478. [PubMed: 19501815]
- Bergen JM, von Recum Ha, Goodman TT, Massey AP, Pun SH. *Macromol Biosci.* 2006; 6:506–516. [PubMed: 16921538]
- Bernardi A, Jiménez-Barbero J, Casnati A, De Castro C, Darbre T, Fieschi F, Finne J, Funken H, Jaeger KE, Lahmann M, Lindhorst TK, Marradi M, Messner P, Molinaro A, Murphy PV, Nativi C, Oscarson S, Penadés S, Peri F, Pieters RJ, Renaudet O, Reymond JL, Richichi B, Rojo J, Sansone F, Schäffer C, Turnbull WB, Velasco-Torrijos T, Vidal S, Vincent S, Wenckes T, Zuilhof H, Imberty A. *Chem Soc Rev.* 2013; 42:4709–4727. [PubMed: 23254759]
- Bhang SH, Won N, Lee T, Jin H, Nam J, Park J, Chung H, Park H, Sung Y, Hahn SK, Kim BS, Kim S. *ACS Nano.* 2009; 3:1389–1398. [PubMed: 19476339]
- Boas U, Heegaard P. *Chem Soc Rev.* 2004; 33:43–63. [PubMed: 14737508]
- Bogdan N, Roy R, Morin M. *RSC Adv.* 2012; 2:985–991.
- Bosman AW, Janssen HM, Meijer EW. *Chem Rev.* 1999; 99:1665–1688. [PubMed: 11849007]
- Branderhorst HM, Kooij R, Salminen A, Jongeneel LH, Arnusch CJ, Liskamp RMJ, Finne J, Pieters RJ. *Org Biomol Chem.* 2008; 6:1425–1434. [PubMed: 18385849]

- Cai XJ, Li XH, Liu YW, Wu GN, Zhao YC, Chen F, Gu ZW. *Pharm Res.* 2012; 29:2167–2179. [PubMed: 22477071]
- Chabre YM, Roy R. *Adv Carbohydr Chem Biochem.* 2010; 63:165–393. [PubMed: 20381707]
- Chen CT, Munot YS, Salunke SB, Wang YC, Lin RK, Lin CC, Chen CC, Liu YH. *Adv Funct Mater.* 2008; 18:527–540.
- Chen QS, Wei WL, Lin JM. *Biosens Bioelectron.* 2011; 26:4497–4502. [PubMed: 21621405]
- Chen X, Lee GS, Zettl A, Bertozzi CR. *Angew Chem Int Ed.* 2004; 43:6111–6116.
- Chen X, Ramström O, Yan M. *Nano Res.* 2014; 7:1381–1403. [PubMed: 26500721]
- Chen X, Tam UC, Czapinski JL, Lee GS, Rabuka D, Zettl A, Bertozzi CR. *J Am Chem Soc.* 2006; 128:6292–6293. [PubMed: 16683774]
- Chen YF, Ji T, Rosenzweig Z. *Nano Lett.* 2003; 3:581–584.
- Chen YJ, Chen SH, Chien YY, Chang YW, Liao HK, Chang CY, Jan MD, Wang KT, Lin CC. *ChemBioChem.* 2005; 6:1169–1173. [PubMed: 15942924]
- Chen YN, Star A, Vidal S. *Chem Soc Rev.* 2013; 42:4532–4542. [PubMed: 23247183]
- Chen YN, Vedala H, Kotchey GP, Audfray A, Cecioni S, Imberty A, Vidal S, Star A. *ACS Nano.* 2012; 6:760–770. [PubMed: 22136380]
- Chien YY, Jan MD, Adak AK, Tzeng HC, Lin YP, Chen YJ, Wang KT, Chen CT, Chen CC, Lin CC. *ChemBioChem.* 2008; 9:1100–9. [PubMed: 18398881]
- Chiodo F, Marradi M, Park J, Ram AFJ, Penadés S, van Die I, Tefsen B. *ACS Chem Biol.* 2014; 9:383–9. [PubMed: 24304188]
- Chuang YJ, Zhou XC, Pan ZW, Turchi C. *Biochem Biophys Res Commun.* 2009; 389:22–27. [PubMed: 19698698]
- Coulon J, Thouvenin I, Aldeek F, Balan L, Schneider R. *J Fluoresc.* 2010; 20:591–597. [PubMed: 20058182]
- Crocker PR, Paulson JC, Varki A. *Nat Rev Immunol.* 2007; 7:255–266. [PubMed: 17380156]
- Cummin BM, Lim J, Simanek EE, Pishko MV, Coté GL. *Biomed Opt Exp.* 2011; 2:1243–1257.
- De la Fuente M, Alcántara D, Penadés S. *IEEE Trans NanoBioscience.* 2007; 6:275–281. [PubMed: 18217620]
- De la Fuente M, Barrientos AG, Rojas TC, Rojo J, Cañada J, Fernández A, Penadés S. *Angew Chem Int Ed.* 2001; 40:2257–2261.
- De la Fuente M, Penadés S. *Tetrahedron Asymmetry.* 2005; 16:387–391.
- Dube DH, Bertozzi CR. *Nat Rev Drug Discov.* 2005; 4:477–488. [PubMed: 15931257]
- El-Boubbou K, Gruden C, Huang XF. *J Am Chem Soc.* 2007; 129:13392–13393. [PubMed: 17929928]
- El-Boubbou K, Huang XF. *Curr Med Chem.* 2011; 18:2060–2078. [PubMed: 21517769]
- El-Boubbou K, Zhu DC, Vasileiou C, Borhan B, Prospero D, Li W, Huang XF. *J Am Chem Soc.* 2010; 132:4490–4499. [PubMed: 20201530]
- El-Dakdouki MH, El-Boubbou K, Kamat M, Huang RP, Abela GS, Kiupel M, Zhu DC, Huang XF. *Pharm Res.* 2014; 31:1426–1437. [PubMed: 23568520]
- El-Dakdouki MH, El-Boubbou K, Zhu DC, Huang X. *RSC Adv.* 2011; 1:1449–1452. [PubMed: 22662307]
- El-Dakdouki MH, Zhu DC, El-Boubbou K, Kamat M, Chen JJ, Li W, Huang XF. *Biomacromolecules.* 2012; 13:1144–1151. [PubMed: 22372739]
- Elvira G, García I, Benito M, Gallo J, Desco M, Penadés S, Garcia-Sanz JA, Silva A. *PLoS One.* 2012; 7:e44466. [PubMed: 22957072]
- Elvira G, García I, Gallo J, Benito M, Montesinos P, Holgado-Martin E, Ayuso-Sacido A, Penadés S, Desco M, Silva A, Garcia-Sanz JA. *Stem Cell Res.* 2015; 14:114–129. [PubMed: 25564310]
- Ernst B, Magnani JL. *Nat Rev Drug Discov.* 2009; 8:661–677. [PubMed: 19629075]
- Farr TD, Lai CH, Grünstein D, Orts-Gil G, Wang C, Boehm-Sturm P, Seeberger PH, Harms C. *Nano Lett.* 2014; 14:2130–2134. [PubMed: 24564342]
- Feng W, Luo RM, Xiao J, Ji PJ, Zheng ZG. *Chem Eng Sci.* 2011; 66:4807–4813.
- Finlay BB, Cossart P. *Science.* 1997; 276:718–725. [PubMed: 9115192]

- Frigell J, García I, Gómez-Vallejo V, Llop J, Penadés S. *J Am Chem Soc.* 2014; 136:449–457. [PubMed: 24320878]
- Furuike T, Sadamoto R, Niikura K, Monde K, Sakairi N, Nishimura SI. *Tetrahedron.* 2005; 61:1737–1742.
- Gallo J, García I, Genicio N, Padro D, Penadés S. *Biomaterials.* 2011; 32:9818–9825. [PubMed: 21940045]
- Gallo J, Genicio N, Penadés S. *Adv Healthc Mater.* 2012; 1:302–307. [PubMed: 23184744]
- Gann JP, Yan M. *Langmuir.* 2008; 24:5319–5323. [PubMed: 18433181]
- Gao J, Li L, Ho PL, Mak GC, Gu H, Xu B. *Adv Mater.* 2006; 18:3145–3148.
- García I, Gallo J, Genicio N, Padro D, Penadés S. *Bioconjugate Chem.* 2011; 22:264–273.
- García I, Marradi M, Penadés S. *Nanomedicine.* 2010; 5:777–792. [PubMed: 20662648]
- García I, Sánchez-Iglesias A, Henriksen-Lacey M, Grzelczak M, Penadés S, Liz-Marzán LM. *J Am Chem Soc.* 2015; 137:3686–3692. [PubMed: 25706836]
- Gary-Bobo M, Mir Y, Rouxel C, Brevet D, Basile I, Maynadier M, Vaillant O, Mongin O, Blanchard-Desce M, Morère A, Garcia M, Durand JO, Raehm L. *Angew Chem Int Ed.* 2011; 50:11425–11429.
- Gorityala BK, Ma JM, Wang X, Chen P, Liu XW. *Chem Soc Rev.* 2010; 39:2925–2934. [PubMed: 20585681]
- Grünstein D, Magliano M, Kikkeri R, Collot M, Barylyuk K, Lepenies B, Kamena F, Zenobi R, Seeberger PH. *J Am Chem Soc.* 2011; 133:13957–13966. [PubMed: 21790192]
- Gu HW, Ho PL, Tsang KWT, Wang L, Xu B. *J Am Chem Soc.* 2003a; 125:15702–15703. [PubMed: 14677934]
- Gu HW, Ho PL, W T, Tsang K, Yu CW, Xu B. *Chem Commun.* 2003b:1966–1967.
- Gu LR, Elkin T, Jiang XP, Li HP, Lin Y, Qu LW, Tzeng TRJ, Joseph R, Sun YP. *Chem Commun.* 2005:874–876.
- Gu LR, Luo PG, Wang H, Meziani MJ, Lin Y, Veca LM, Cao L, Lu FS, Wang X, Quinn RA, Wang W, Zhang PY, Lacher S, Sun YP. *Biomacromolecules.* 2008; 9:2408–2418. [PubMed: 18712920]
- Guo YL, Yan HT. *J Carbohydr Chem.* 2008; 27:309–319.
- Halkes KM, Carvalho de Souza A, Maljaars CEP, Gerwig GJ, Kamerling JP. *Eur J Org Chem.* 2005; 2005:3650–3659.
- Han E, Ding L, Jin S, Ju HX. *Biosens Bioelectron.* 2011a; 26:2500–2505. [PubMed: 21112760]
- Han E, Ding L, Ju HX. *Anal Chem.* 2011b; 83:7006–7012. [PubMed: 21809847]
- Hansen HC, Haataja S, Finne J, Magnusson G. *J Am Chem Soc.* 1997; 119:6974–6979.
- Hao NJ, Li LL, Zhang Q, Huang XL, Meng XW, Zhang YQ, Chen D, Tang FQ, Li LL. *Microporous Mesoporous Mater.* 2012; 162:14–23.
- Hao NJ, Jayawardana KW, Chen X, Yan M. *ACS Appl Mater Interfaces.* 2015; 7:1040–1045. [PubMed: 25562524]
- Hao NJ, Li LF, Tang FQ. *J Biomed Nanotechnol.* 2014a; 10:2508–2538. [PubMed: 25992407]
- Hao NJ, Li LF, Tang FQ. *J Mater Chem A.* 2014b; 2:11565–11568.
- Harada YH, Murata TM, Totani KT, Kajimoto TK, Masum SM, Tamba YT, Yamazaki MY, Usui TU. *Biosci Biotechnol Biochem.* 2005; 69:166–178. [PubMed: 15665482]
- Hartmann M, Betz P, Sun Y, Gorb SN, Lindhorst TK, Krueger A. *Chem Eur J.* 2012; 18:6485–6492. [PubMed: 22528128]
- Hasegawa T, Fujisawa T, Numata M, Umeda M, Matsumoto T, Kimura T, Okumura S, Sakurai K, Shinkai S. *Chem Commun.* 2004:2150–2151.
- Hatano K, Saeki H, Yokota H, Aizawa H, Koyama T, Matsuoka K, Terunuma D. *Tetrahedron Lett.* 2009; 50:5816–5819.
- Hatch DM, Weiss Aa, Kale RR, Iyer SS. *ChemBioChem.* 2008; 9:2433–2442. [PubMed: 18803208]
- He Y, Fan CH, Lee ST. *Nano Today.* 2010; 5:282–295.
- Higuchi Y, Oka M, Kawakami S, Hashida M. *J Control Release.* 2008; 125:131–136. [PubMed: 18045722]
- Hildebrand A, Schaedlich A, Rothe U, Neubert RHH. *J Colloid Interf Sci.* 2002; 249:274–281.



- Hocine O, Gary-Bobo M, Brevet D, Maynadier M, Fontanel S, Raehm L, Richeter S, Loock B, Couleaud P, Frochot C. *Int J Clin Pharm.* 2010; 402:221–230.
- Holgerrsson J, Gustafsson A, Breimer ME. *Immunol Cell Biol.* 2005; 83:694–708. [PubMed: 16266322]
- Holzinger M, Abraham J, Whelan P, Graupner R, Ley L, Hennrich F, Kappes M, Hirsch A. *J Am Chem Soc.* 2003; 125:8566–8580. [PubMed: 12848565]
- Hone DC, Haines AH, Russell DA. *Langmuir.* 2003; 19:7141–7144.
- Hong SY, Tobias G, Al-Jamal KT, Ballesteros B, Ali-Boucetta H, Lozano-Perez S, Nellist PD, Sim RB, Finucane C, Mather SJ, Green MLH, Kostarelos K, Davis BG. *Nat Mater.* 2010; 9:485–490. [PubMed: 20473287]
- Horak D, Babic M, Jendelová P, Herynek V, Trchová M, Pientka Z, Pollert E, Hájek M, Syková E. *Bioconjugate Chem.* 2007; 18:635–644.
- Hu FX, Chen SH, Wang CY, Yuan R, Xiang Y, Wang C. *Biosens Bioelectron.* 2012; 34:202–207. [PubMed: 22387041]
- Hu, XLe; Jin, HY.; He, XP.; James, TD.; Chen, GR.; Long, YT. *ACS Appl Mater Interfaces.* 2015; 7:1874–1878. [PubMed: 25531131]
- Huang CC, Chen CT, Shiang YC, Lin ZH, Chang HT. *Anal Chem.* 2009; 81:875–882. [PubMed: 19119843]
- Huang CF, Yao GH, Liang RP, Qiu JD. *Biosens Bioelectron.* 2013; 50:305–310. [PubMed: 23876541]
- Huang, LDe; Adak, AK.; Yu, CC.; Hsiao, WC.; Lin, HJ.; Chen, ML.; Lin, CC. *Chem Eur J.* 2015; 21:3956–3967. [PubMed: 25571858]
- Huang GL. *Curr Med Chem.* 2013; 20:782–788. [PubMed: 23276135]
- Hulikova K, Benson V, Svoboda J, Sima P, Fiserova A. *Int Immunopharmacol.* 2009; 9:792–799. [PubMed: 19303462]
- Hulikova K, Svoboda J, Benson V, Grobarova V, Fiserova A. *Int Immunopharmacol.* 2011; 11:955–961. [PubMed: 21349367]
- Ibey BL, Beier HT, Rounds RM, Coté GL, Yadavalli VK, Pishko MV. *Anal Chem.* 2005; 77:7039–7046. [PubMed: 16255607]
- Jayaraman N. *Chem Soc Rev.* 2009; 38:3463–3483. [PubMed: 20449063]
- Jayaraman N, Maiti K, Naresh K. *Chem Soc Rev.* 2013; 42:4640–4656. [PubMed: 23487184]
- Jayawardena HSN, Jayawardana KW, Chen X, Yan M. *Chem Commun.* 2013a; 49:3034–3036.
- Jayawardena HSN, Wang X, Yan M. *Anal Chem.* 2013b; 85:10277–10281. [PubMed: 24079754]
- Jayawardana KW, Jayawardana HSN, Wijesundera SA, De Zoysa T, Sundhoro M, Yan M. *Chem Commun.* 201510.1039/C5CC04251H
- Jiang K, Wang X, Geng H, Beer TM, Qian DZ, Ramström O, Yan M. *ScienceJet.* 2015; 4:132.
- Jiang XZ, Housni A, Gody G, Boullanger P, Charreyre MT, Delair T, Narain R. *Bioconjugate Chem.* 2010; 21:521–530.
- Joosten JAF, Loimaranta V, Appeldoorn CCM, Haatja S, El Maate FA, Liskamp RMJ, Finne J, Pieters RJ. *J Med Chem.* 2004; 47:6499–6508. [PubMed: 15588085]
- Kamat M, El-Boubbou K, Zhu DC, Lansdell T, Lu XW, Li W, Huang XF. *Bioconjugate Chem.* 2010; 21:2128–2135.
- Kato H, Yashiro A, Mizuno A, Nishida Y, Kobayashi K, Shinohara H. *Bioorg Med Chem Lett.* 2001; 11:2935–2939. [PubMed: 11677130]
- Kato T, Kawaguchi A, Nagata K, Hatanaka K. *Biochem Biophys Res Commun.* 2010; 394:200–204. [PubMed: 20188703]
- Kell AJ, Stewart G, Ryan S, Peytavi R, Boissinot M, Huletsky A, Bergeron MG, Simard B. *ACS Nano.* 2008; 2:1777–1788. [PubMed: 19206416]
- Kelly KL, Coronado E, Zhao LL, Schatz GC. *J Phys Chem B.* 2003; 107:668–677.
- Kemp MM, Kumar A, Mousa S, Dyskin E, Yalcin M, Ajayan P, Linhardt RJ, Mousa SA. *Nanotechnology.* 2009; 20:455104. [PubMed: 19822927]
- Khlar N, Leal MP, Baati R, Ruhlmann C, Mioskowski C, Schultz P, Fernández I. *Chem Commun.* 2009:4121–4123.

- Kiessling LL, Gestwicki JE, Strong LE. *Angew Chem Int Ed*. 2006; 45:2348–2368.
- Kikkeri R, García-Rubio I, Seeberger PH. *Chem Commun*. 2009a:235–237.
- Kikkeri R, Grünstein D, Seeberger PH. *J Am Chem Soc*. 2010a; 132:10230–10232. [PubMed: 20662498]
- Kikkeri R, Hossain LH, Seeberger PH. *Chem Commun*. 2008:2127–2129.
- Kikkeri R, Kamena F, Gupta T, Hossain LH, Boonyarattanakalin S, Gorodyska G, Beurer E, Coullerez G, Textor M, Seeberger PH. *Langmuir*. 2010b; 26:1520–1523. [PubMed: 20099915]
- Kikkeri R, Lepenies B, Adibekian A, Laurino P, Seeberger PH. *J Am Chem Soc*. 2009b; 131:2110–2112. [PubMed: 19199612]
- Kim KS, Hur W, Park SJ, Hong SW, Choi JE, Goh EJ, Yoon SK, Hahn SK. *ACS Nano*. 2010; 4:3005–3014. [PubMed: 20518553]
- Kong N, Shimpi MR, Ramström O, Yan M. *Carbohydr Res*. 2015; 405:33–38. [PubMed: 25746392]
- Kouyoumdjian H, Zhu DC, El-Dakdouki MH, Lorenz K, Chen JJ, Li W, Huang XF. *ACS Chem Neurosci*. 2013; 4:575–584. [PubMed: 23590250]
- Krist P, Vannucci L, Kuzma M, Man P, Sadalapure K, Patel A, Bezouska K, Pospíšil M, Petrus L, Lindhorst TK, Kren V. *ChemBioChem*. 2004; 5:445–452. [PubMed: 15185367]
- Kulkarni AA, Fuller C, Korman H, Weiss AA, Iyer SS. *Bioconjugate Chem*. 2010; 21:1486–1493.
- Kumar A, Sahoo B, Montpetit A, Behera S, Lockey RF, Mohapatra SS. *Nanomedicine*. 2007; 3:132–137. [PubMed: 17572355]
- La Belle JT, Gerlach JQ, Svarovsky S, Joshi L. *Anal Chem*. 2007; 79:6959–6964. [PubMed: 17658764]
- Lasala F, Arce E, Otero JR, Rojo J, Delgado R. *Antimicrob Agents Chemother*. 2003; 47:3970–3972. [PubMed: 14638512]
- Lee H, Lee K, Kim IK, Park TG. *Biomaterials*. 2008; 29:4709–4718. [PubMed: 18817971]
- Lee Y, Lee H, Kim YB, Kim J, Hyeon T, Park H, Messersmith PB, Park TG. *Adv Mater*. 2008; 20:4154–4157. [PubMed: 19606262]
- Lee YC, Lee RT. *Acc Chem Res*. 1995; 28:321–327.
- Li HG, El-Dakdouki MH, Zhu DC, Abela GS, Huang XF. *Chem Commun*. 2012; 48:3385–3387.
- Li X, Zhou HY, Yang L, Du GQ, Pai-Panandiker AS, Huang XF, Yan B. *Biomaterials*. 2011; 32:2540–2545. [PubMed: 21232787]
- Lim KR, Park JM, Choi HN, Lee WY. *Microchem J*. 2013; 106:154–159.
- Lin CC, Yeh YC, Yang CY, Chen GF, Chen YC, Wu YC, Chen CC. *Chem Commun*. 2003:2920–2921.
- Lin PC, Ueng Shua, Yu SC, Jan Mdan, Adak AK, Yu CC, Lin CC. *Org Lett*. 2007; 9:2131–2134. [PubMed: 17477538]
- Liu FT, Rabinovich GA. *Nat Rev Cancer*. 2005; 5:29–41. [PubMed: 15630413]
- Liu L, Yan M. *Angew Chem Int Ed*. 2006; 45:6207–6210.
- Liu LH, Dietsch H, Schurtenberger P, Yan M. *Bioconjugate Chem*. 2009; 20:1349–1355.
- Liu LH, Lerner MM, Yan M. *Nano Lett*. 2010a; 10:3754–3756. [PubMed: 20690657]
- Liu LH, Yan M. *Acc Chem Res*. 2010; 43:1434–1443. [PubMed: 20690606]
- Liu LH, Zorn G, Castner DG, Solanki R, Lerner MM, Yan M. *J Mater Chem*. 2010b; 20:5041–5046. [PubMed: 24155570]
- Liu RR, Liew RS, Zhou J, Xing BG. *Angew Chem Int Ed*. 2007; 46:8799–8803.
- Liu Y, Zhao YL, Sun BY, Chen CY. *Acc Chem Res*. 2012; 46:702–713. [PubMed: 22999420]
- Lu M, Cohen MH, Rieves D, Pazdur R. *Am J Hematol*. 2010; 85:315–319. [PubMed: 20201089]
- Luczkowiak J, Muñoz A, Sánchez-Navarro M, Ribeiro-Viana R, Ginieis A, Illescas BM, Martín N, Delgado R, Rojo J. *Biomacromolecules*. 2013; 14:431–437. [PubMed: 23281578]
- Lyu YK, Lim KR, Lee BY, Kim KS, Lee WY. *Chem Commun*. 2008:4771–4773.
- Maalouli N, Barras A, Siriwardena A, Bouazaoui M, Boukherroub R, Szunerits S. *Analyst*. 2013; 138:805–812. [PubMed: 23223216]
- Mahon E, Aastrup T, Barboiu M. *Chem Commun*. 2010a; 46:5491–5493.

- Mahon E, Aastrup T, Barboiu M. *Chem Commun.* 2010b; 46:2441–2443.
- Mahon E, Mouline Z, Sillion M, Gilles A, Pinteala M, Barboiu M. *Chem Commun.* 2013; 49:3004–3006.
- Marín MJ, Rashid A, Rejzek M, Fairhurst SA, Wharton SA, Martin SR, McCauley JW, Wileman T, Field RA, Russell DA. *Org Biomol Chem.* 2013; 11:7101–7107. [PubMed: 24057694]
- Marradi M, Alcántara D, de la Fuente JM, García-Martín ML, Cerdán S, Penadés S. *Chem Commun.* 2009:3922–3924.
- Marradi M, Chiodo F, García I, Penadés S. *Chem Soc Rev.* 2013; 42:4728–4745. [PubMed: 23288339]
- Martos-Maldonado MC, Casas-Solvas JM, Quesada-Soriano I, García-Fuentes L, Vargas-Berenguel A. *Langmuir.* 2013; 29:1318–1326. [PubMed: 23286545]
- McLean JA, Stumpo KA, Russell DH. *J Am Chem Soc.* 2005; 127:5304–5305. [PubMed: 15826152]
- Michalet X, Pinaud FF, Bentolila LA, Tsay JM, Doose S, Li JJ, Sundaresan G, Wu AM, Gambhir SS, Weiss S. *Science.* 2005; 307:538–544. [PubMed: 15681376]
- Min IH, Choi L, Ahn KS, Kim BK, Lee BY, Kim KS, Choi HN, Lee WY. *Biosens Bioelectron.* 2010; 26:1326–1331. [PubMed: 20685103]
- Mukhopadhyay B, Martins MB, Karamanska R, Russell DA, Field RA. *Tetrahedron Lett.* 2009; 50:886–889.
- Munoz EM, Correa J, Fernandez-Megia E, Riguera R. *J Am Chem Soc.* 2009; 131:17765–17767. [PubMed: 19919053]
- Munoz EM, Correa J, Riguera R, Fernandez-Megia E. *J Am Chem Soc.* 2013; 135:5966–5969. [PubMed: 23565759]
- Murray RA, Qiu Y, Chiodo F, Marradi M, Penadés S, Moya SE. *Small.* 2014; 10:2602–2610. [PubMed: 24639360]
- Murthy BN, Zeile S, Nambiar M, Nussio MR, Gibson CT, Shapter JG, Jayaraman N, Voelcker NH. *RSC Adv.* 2012; 2:1329–1333.
- Nagahori N, Lee RT, Nishimura S, Page D, Roy R, Lee YC. *ChemBioChem.* 2002; 3:836–844. [PubMed: 12210984]
- Narla SN, Sun X. *Biomacromolecules.* 2012; 13:1675–1682. [PubMed: 22519294]
- Nath S, Kaittanis C, Tinkham A, Perez JM. *Anal Chem.* 2008; 80:1033–1038. [PubMed: 18198893]
- Niikura K, Nishio T, Akita H, Matsuo Y, Kamitani R, Kogure K, Harashima H, Ijiro K. *ChemBioChem.* 2007; 8:379–384. [PubMed: 17243188]
- Niikura K, Sekiguchi S, Nishio T, Masuda T, Akita H, Matsuo Y, Kogure K, Harashima H, Ijiro K. *ChemBioChem.* 2008; 9:2623–2627. [PubMed: 18821556]
- Nimmagadda A, Thurston K, Nollert MU, McFetridge PS. *J Biomed Mater Res A.* 2006; 76:614–625. [PubMed: 16315191]
- Ohyanagi T, Nagahori N, Shimawaki K, Hinou H, Yamashita T, Sasaki A, Jin T, Iwanaga T, Kinjo M, Nishimura SI. *J Am Chem Soc.* 2011; 133:12507–12517. [PubMed: 21740000]
- Ortega-Caballero F, Giménez-Martínez JJ, García-Fuentes L, Ortiz-Salmerón E, Santoyo-González F, Vargas-Berenguel A. *J Org Chem.* 2001; 66:7786–7795. [PubMed: 11701037]
- Osaki F, Kanamori T, Sando S, Sera T, Aoyama Y. *J Am Chem Soc.* 2004; 126:6520–6521. [PubMed: 15161257]
- Otsuka H, Akiyama Y, Nagasaki Y, Kataoka K. *J Am Chem Soc.* 2001; 123:8226–8230. [PubMed: 11516273]
- Park J, Jayawardena HSN, Chen X, Jayawardana KW, Sundhoro M, Ada E, Yan M. *Chem Commun.* 2015; 51:2882–2885.
- Park J, Yan M. *Acc Chem Res.* 2013; 46:181–189. [PubMed: 23116448]
- Peng J, Wang K, Tan W, He X, He C, Wu P, Liu F. *Talanta.* 2007; 71:833–840. [PubMed: 19071382]
- Pera NP, Kouki A, Haataja S, Branderhorst HM, Liskamp RMJ, Visser GM, Finne J, Pieters RJ. *Org Biomol Chem.* 2010; 8:2425–2429. [PubMed: 20448902]
- Perrier M, Gary-Bobo M, Lartigue L, Brevet D, Morère A, Garcia M, Maillard P, Raehm L, Guari Y, Larionova J, Durand JO, Mongin O, Blanchard-Desce M. *J Nanopart Res.* 2013; 15:1602.

- Pfaff A, Schallon A, Ruhland TM, Majewski AP, Schmalz H, Freitag R, Müller AHE. *Biomacromolecules*. 2011; 12:3805–3811. [PubMed: 21875143]
- Pinson J, Podvorica F. *Chem Soc Rev*. 2005; 34:429–439. [PubMed: 15852155]
- Ponader D, Wojcik F, Beceren-Braun F, Dervede J, Hartmann L. *Biomacromolecules*. 2012; 13:1845–1852. [PubMed: 22483345]
- Prato M. *J Mater Chem*. 1997; 7:1097–1109.
- Prato M, Li QC, Wudl F, Lucchini V. *J Am Chem Soc*. 1993; 115:1148–1150.
- Qi, GBin; Li, LL.; Yu, FQ.; Wang, H. *ACS Appl Mater Interfaces*. 2013; 5:10874–10881. [PubMed: 24131516]
- Ragoussi ME, Casado S, Ribeiro-Viana R, Torre GDLA, Rojo J, Torres T. *Chem Sci*. 2013; 4:4035–4041.
- Reichardt NC, Martín-Lomas M, Penadés S. *Chem Soc Rev*. 2013; 42:4358–4376. [PubMed: 23303404]
- Reichert A, Nagy JO, Spevak W, Charych D. *J Am Chem Soc*. 1995; 117:829–830.
- Reynolds M, Marradi M, Imberty A, Penadés S, Pérez S. *Chem Eur J*. 2012; 18:4264–4273. [PubMed: 22362615]
- Robinson A, Fang JM, Chou PT, Liao KW, Chu RM, Lee SJ. *ChemBioChem*. 2005; 6:1899–1905. [PubMed: 16149042]
- Rojo J, Díaz V, de la Fuente JM, Segura I, Barrientos AG, Riese HH, Bernad A, Penadés S. *ChemBioChem*. 2004; 5:291–297. [PubMed: 14997521]
- Saha K, Agasti SS, Kim C, Li X, Rotello VM. *Chem Rev*. 2012; 112:2739–2779. [PubMed: 22295941]
- Salminen A, Loimaranta V, Joosten JaF, Khan aS, Hacker J, Pieters RJ, Finne J. *J Antimicrob Chemother*. 2007; 60:495–501. [PubMed: 17623698]
- Sánchez-Navarro M, Muñoz A, Illescas BM, Rojo J, Martín N. *Chem Eur J*. 2011; 17:766–769. [PubMed: 21226088]
- Sandros MG, Behrendt M, Maysinger D, Tabrizian M. *Adv Funct Mater*. 2007; 17:3724–3730.
- Schlick KH, Lange CK, Gillispie GD, Cloninger MJ. *J Am Chem Soc*. 2009; 131:16608–16609. [PubMed: 19873969]
- Schofield CL, Field RA, Russell DA. *Anal Chem*. 2007; 79:1356–1361. [PubMed: 17297934]
- Schofield CL, Mukhopadhyay B, Hardy SM, McDonnell MB, Field RA, Russell DA. *Analyst*. 2008; 133:626–634. [PubMed: 18427684]
- Seebach D, Rheiner BP, Greiveldinger G, Butz T, Sellner H. *Top Curr Chem*. 1998; 197:125–164.
- Seto H, Kamba S, Kondo T, Hasegawa M, Nashima S, Ehara Y, Ogawa Y, Hoshino Y, Miura Y. *ACS Appl Mater Interfaces*. 2014; 6:13234–13241. [PubMed: 25014128]
- Seto H, Ogata Y, Murakami T, Hoshino Y, Miura Y. *ACS Appl Mater Interfaces*. 2012; 4:411–417. [PubMed: 22148732]
- Shaunak S, Thomas S, Gianasi E, Godwin A, Jones E, Teo I, Mireskandari K, Luthert P, Duncan R, Patterson S, Khaw P, Brocchini S. *Nat Biotechnol*. 2004; 22:977–984. [PubMed: 15258595]
- Shi ZL, Neoh KG, Kang ET, Shuter B, Wang SC, Poh C, Wang W. *ACS Appl Mater Interfaces*. 2009; 1:328–335. [PubMed: 20353220]
- Slowing II, Trewyn BG, Giri S, Lin VSY. *Adv Funct Mater*. 2007; 17:1225–1236.
- Srinivasan B, Huang XF. *Chirality*. 2008; 20:265–277. [PubMed: 17568438]
- Sudibya HG, Ma JM, Dong XC, Ng S, Li LJ, Liu XW, Chen P. *Angew Chem Int Ed*. 2009; 48:2723–2726.
- Sunasee R, Narain R. *Macromol Biosci*. 2013; 13:9–27. [PubMed: 23042762]
- Sundgren A, Barchi JJ. *Carbohydr Res*. 2008; 343:1594–1604. [PubMed: 18502409]
- Svarovsky SA, Szekely Z, Barchi JJ. *Tetrahedron Asymmetry*. 2005; 16:587–598.
- Szymanski CM, Wren BW. *Nat Rev Microbiol*. 2005; 3:225–237. [PubMed: 15738950]
- Tanaka T, Inoue G, Shoda SI, Kimura Y. *J Polym Sci Part A Polym Chem*. 2014a; 52:3513–3520.
- Tanaka T, Ishitani H, Miura Y, Oishi K, Takahashi T, Suzuki T, Shoda S, Kimura Y. *ACS Macro Lett*. 2014b; 3:1074–1078.

- Terada Y, Hashimoto W, Endo T, Seto H, Murakami T, Hisamoto H, Hoshino Y, Miura Y. *J Mater Chem B*. 2014; 2:3324–3332.
- Thygesen MB, Sauer J, Jensen KJ. *Chem Eur J*. 2009; 15:1649–1660. [PubMed: 19115306]
- Tong Q, Wang X, Wang H, Kubo T, Yan M. *Anal Chem*. 2012; 84:3049–3052. [PubMed: 22385080]
- Touaibia M, Wellens A, Shiao TC, Wang Q, Sirois S, Bouckaert J, Roy R. *ChemMedChem*. 2007; 2:1190–1201. [PubMed: 17589887]
- Trewyn BG, Giri S, Slowing II, Lin VSY. *Chem Commun*. 2007; 43:3236–3245.
- Tsai CS, Yu TBin, Chen CT. *Chem Commun*. 2005:4273–4275.
- Turnbull WB, Kalovidouris Sa, Stoddart JF. *Chem Eur J*. 2002; 8:2988–3000. [PubMed: 12489230]
- Van Kasteren SI, Campbell SJ, Serres S, Anthony DC, Sibson NR, Davis BG. *Proc Natl Acad Sci U S A*. 2008; 106:18–23. [PubMed: 19106304]
- Vedantam P, Tzeng TRJ, Brown AK, Podila R, Rao A, Staley K. *Plasmonics*. 2012; 7:301–308.
- Voit B, Appelhans D. *Macromol Chem Phys*. 2010; 211:727–735.
- Wang H, Ren J, Hlaing A, Yan M. *J Colloid Interf Sci*. 2011; 354:160–167.
- Wang HF, Gu LR, Lin Y, Lu FS, Mezziani MJ, Luo PG, Wang W, Cao L, Sun YP. *J Am Chem Soc*. 2006; 128:13364–13365. [PubMed: 17031942]
- Wang X, Liu LH, Ramström O, Yan M. *Exp Biol Med*. 2009a; 234:1128–1139.
- Wang X, Matei E, Deng L, Koharudin L, Gronenborn AM, Ramström O, Yan M. *Biosens Bioelectron*. 2013; 47:258–264. [PubMed: 23584388]
- Wang X, Matei E, Deng L, Ramström O, Gronenborn AM, Yan M. *Chem Commun*. 2011a; 47:8620–8622.
- Wang X, Matei E, Gronenborn AM, Ramström O, Yan M. *Anal Chem*. 2012; 84:4248–4252. [PubMed: 22548468]
- Wang X, Ramström O, Yan M. *J Mater Chem*. 2009b; 19:8944–8949. [PubMed: 20856694]
- Wang X, Ramström O, Yan M. *Adv Mater*. 2010a; 22:1946–1953. [PubMed: 20301131]
- Wang X, Ramström O, Yan M. *Anal Chem*. 2010b; 82:9082–9089. [PubMed: 20942402]
- Wang X, Ramström O, Yan M. *Analyst*. 2011b; 136:4174–4178. [PubMed: 21858301]
- Wang X, Ramström O, Yan M. *Chem Commun*. 2011c; 47:4261–4263.
- Wang Y, Narain R, Liu Y. *Langmuir*. 2014; 30:7377–7387. [PubMed: 24885262]
- Wang YX, Hussain SM, Krestin GP. *Eur Radiol*. 2001; 11:2319–2331. [PubMed: 11702180]
- Wang ZX, Ma LN. *Coord Chem Rev*. 2009; 253:1607–1618.
- Wu P, Chen X, Hu N, Tam UC, Blixt O, Zettl A, Bertozzi CR. *Angew Chem Int Ed*. 2008; 47:5022–5025.
- Wudl F. *J Mater Chem*. 2002; 12:1959–1963.
- Yan F, Xue J, Zhu J, Marchant RE, Guo Z. *Bioconjugate Chem*. 2005; 16:90–96.
- Yan M, Harnish B. *Adv Mater*. 2003; 15:244–248.
- Yan M, Ren J. *Chem Mater*. 2004; 16:1627–1632.
- Yang Y, Yu M, Yan TT, Zhao ZH, Sha YL, Li ZJ. *Bioorg Med Chem*. 2010a; 18:5234–5240. [PubMed: 20566293]
- Yang Y, Zhao YT, Yan TT, Yu M, Sha YL, Zhao ZH, Li ZJ. *Tetrahedron Lett*. 2010b; 51:4182–4185.
- Yilmaz G, Becer CR. *Eur Polym J*. 2013; 49:3046–3051.
- Yoo MK, Kim IY, Kim EM, Jeong HJ, Lee CM, Jeong YY, Akaike T, Cho CS. *J Biomed Biotechnol*. 2007; 2007:94740. [PubMed: 18317519]
- Yoo MK, Park IY, Kim IY, Park IK, Kwon JS, Jeong HJ, Jeong YY, Cho CS. *J Nanosci Nanotechnol*. 2008; 8:5196–5202. [PubMed: 19198420]
- Yu L, Huang M, Wang PG, Zeng X. *Anal Chem*. 2007; 79:8979–8986. [PubMed: 17973352]
- Zeng HJ, Yu JS, Jiang YD, Zeng XQ. *Biosens Bioelectron*. 2014; 55:157–161. [PubMed: 24373955]
- Zhao JS, Liu YF, Park HJ, Boggs JM, Basu A. *Bioconjugate Chem*. 2012; 23:1166–1173.
- Zhou J, Butchosa N, Jayawardena HSN, Zhou Q, Yan M, Ramström O. *Bioconjug Chem*. 2014; 25:640–643. [PubMed: 24625204]

- Zhou J, Butchosa N, Jayawardena HSN, Park J, Zhou Q, Yan M, Ramström O. *Biomacromolecules*. 2015a; 16:1426–1432. [PubMed: 25738860]
- Zhou J, Hao NJ, De Zoyza T, Yan M, Ramström O. *Chem Commun*. 2015b; 51:9833–9836.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript




### Highlights


- Glyconanomaterials have witnessed rapid development in the past decade
- A wide variety of glyconanomaterials have been developed and synthesized
- Glyconanomaterials have demonstrated high potential in sensing and imaging proteins, microbes, and cells in vitro and in vivo



**Fig. 1.** Schematic illustration of typical carbohydrate-mediated interactions at cell surfaces. Reproduced from (Holgerson et al., 2005) by permission from Nature Publishing Group.




**Fig. 2.** Gold glyconanoparticles for lectin recognition. Amino-terminated lactose was conjugated to the aldehyde-presenting gold nanoparticles by reductive amination. The resulting glyconanomaterials were subsequently applied to *Ricinus communis* (castor bean) agglutinin (RCA<sub>120</sub>), resulting in significant aggregation and color changes. Reproduced from (Otsuka et al., 2001) with permission from the American Chemical Society.




**Fig. 3.**

QCM sensor using gold glyconanoparticles. (a) Glyconanoparticles were prepared by treating gold nanoparticles with thiolated mannose. (b) Gold-plated QCM sensors were coated with mannan, to which ConA was adsorbed. The Man-conjugated gold nanoparticles were subsequently introduced, and bound to the protein surface through multivalent interactions. Repeated administration of protein and glyconanoparticles resulted in multilayer formation. Reproduced from (Mahon et al., 2013) by permission from the Royal Society of Chemistry.




**Figure 4.** Electrochemical sensing of lectins using glycodendrimers. (a) Structures of mannose-terminated, ferrocene-containing, PAMAM-based glycodendrimers of different generations. (b) Differential pulse voltammery showing decrease in the peak current upon binding of Mandendrimer with ConA. Adapted from (Martos-Maldonado et al. 2013) with permission from American Chemical Society.



**Fig. 5.**

(a) Sialic acid-presenting glycolipid formed glycoliposome which was then crosslinked by irradiation to give a blue- or purple-colored liposome. (b) When influenza virus was added to the liposome, the solution changed to a pink or orange color. The colorimetric response was quantified by measuring the percent change in the absorption at 626 nm relative to the total absorption maxima, and the response increased with the amount of influenza virus added. Adapted from (Reichert et al. 1995) with permission from American Chemical Society.





**Fig. 6.** Antimetastatic effect of lactose-functionalized gold glyconanoparticles (GNPs) on lung tumor development in mice. (A) Evaluation of nanomaterials antimetastatic performance. (B) Lung images displaying lung tumoral foci. (C) Mouse lung tissue treated with murine melanoma cells (B16F10) and GNPs. Reproduced from (Rojo et al., 2004) by permission of Wiley-VCH.

Table 1

Sensing and imaging proteins using gold-, carbon-, polymer-, and dendrimer-glyconanomaterials.

Carbohydrate	Particle size/type	Coupling method (function at group)	Carbohydrate density	Protein types	Detection methods/assay	Detection range/init	Selectivity	References
Gold glyconanomaterials								
Lac; D-Gal	8.9 nm	Covalent (-SH)	20-50 wt%	RCA120	UV-Vis; visualization	5-50 µg/mL; 1 µg/mL (1 ppm)	Lac/RCA120	(Otsuka et al., 2001)
α-D-Man	16 nm	Covalent (-SH)		ConA	UV-Vis	0.192-0.385 µM; <0.1 µM	α-D-Man/ConA	(Hone et al., 2003)
α-D-Man; D-Glc; D-Gal	6-20 nm	Covalent (-SH)	11-128/particle	ConA	SPR	0.095-6 µM	α-D-Man/ConA	(Lin et al., 2003)
α-D-Man; D-Glc	1.79-3.84 nm	Covalent (-SH)	23-98/particle	ConA	SPR; UV-Vis	400-7000 RU	α-D-Man/ConA	(Haikes et al., 2005)
D-GalNAc	1-12 nm	Covalent (-SH)	90/particle	PNA; PSA	UV-Vis		GalNAc/PNA	(Svarovsky et al., 2005)
α-D-Man	32 nm	Covalent (-SH)		ConA; BS-I; SBA; MAL	SPR; UV-Vis; visualization	5 nM	α-D-Man/ConA	(Tsuji et al., 2005)
β-D-Gal	50-150 nm	Covalent (-SH)	4/nm <sup>2</sup>	RCA120	UV-Vis	100 µg/mL	β-Lac/RCA120	(Bergen et al., 2006)
Heparan sulfate	15-16 nm	Covalent (-sulfate)		Heparanase	UV-Vis; visualization	0.7-5.6 µg/mL	Heparan/Heparanase	(Ban et al., 2008)
α-D-Man	~8 nm	Covalent (-SH)		ConA	QCM	1.3×10 <sup>-10</sup> M	α-D-Man/ConA	(Lyu et al., 2008)
β-D-Gal; α-D-Man	16 nm	Covalent (-SH)		RCA120; ConA; BSA	UV-Vis	0.01-0.8 nM (Gal); 0.7-2.4 µM (Man)	Lac/RCA120; α-D-Man/ConA	(Schofield et al., 2008)
Lac; maltose	1.8 nm	Covalent (-SH)	15-50 wt%	β-galactosidase	UV-Vis	0.01-0.1 mg/mL	β-Lac/β-galactosidase	(Barricentes et al., 2009)
maltose; D-Man; D-Glc; Lac	12.33 nm	Covalent (native)		ConA	UV-Vis	0.03-100 nM	α-D-Man/ConA	(Chuang et al., 2009)
α-D-Man	2.9 nm	Covalent (-SH)		ConA; BSA	Fluorescence	0.015-100 nM; 10 pM	α-D-Man/ConA	(Huang et al., 2009)
α-D-Glc; maltose; maltotriose	12 nm	Covalent (-SH)	300-1000 moliigand/mol particles	ConA; GS-II; PNA	UV-Vis	1 µM	α-D-Glc/ConA	(Thygesen et al., 2009)
α-D-Man; Man(1-4)Man	~20 nm	Photocoupling (native)	1200/particle	ConA; GS-II; PNA	UV-Vis; SPR	10 µg/mL	α-D-Man/ConA	(Wang et al., 2009b)
α-D-Man; D-GlcNAc	4-6 nm	Covalent (-SH)	4-52/particle	ConA; WGA	Diffraction optical technology		α-D-Man/ConA; GlcNAc/WGA	(Jiang et al., 2010)
D-Man	10 nm	Covalent (-SH)		ConA; human IgG	Anodic stripping voltammetry	0.084-50 µg/mL; 0.07 µg/mL	Man/ConA	(Min et al., 2010)
D-Man; D-Glc	7-30 nm	Photocoupling (native)	297-4486/particle	ConA	UV-Vis; fluorescence microscopy	0.01-0.32 µM; 16 nM	Man/ConA	(Wang et al., 2010b)
α-D-Man	22 nm	Photocoupling (native)	1037-1516/particle	Cyanovirin	UV-Vis; fluorescence microscopy	100 nM	α-D-Man/Cyanovirin	(Wang et al., 2011a)
D-Man; D-Gal	13-16 nm	Photocoupling (native)		ConA; RCA120	DLS	2.9 nM	D-Man/ConA	(Wang et al., 2011b)
β-D-Gal; β-D-Glc; α-D-Man	1.2-1.7 nm	Covalent (-SH)	11-67/particle	PA-IL	SPR; ITC	300 RU	β-D-Gal/PA-IL	(Reynolds et al., 2012)
D-Man; D-Gal	22 nm	Photocoupling (native)	3600/particle	ConA	ITC	10 µM	D-Man/ConA	(Wang et al., 2012)
Dextran		Covalent (native)		ConA	SPR	1-20 µg/mL; 0.39 µg/mL	Dex/ConA	(Huang et al., 2013)
D-Man; D-GlcNAc; Lac; D-Gal; Lac; sucrose; D-Ara; D-Glc	20 nm	Photocoupling (native)		ConA; GS-II; PNA; SBA	UV-Vis	10 µg/mL	D-Man/ConA; D-GlcNAc/GS-II; Lac/PNA; D-Gal/SBA	(Jayawardena et al., 2013b)
D-Man	10 nm	Covalent (-SH)		ConA	UV-Vis	10-50 µg/mL	D-Man/ConA	(Lim et al., 2013)
α-D-Man	12.5 nm	Covalent (-SH)		ConA	QCM	1 µM	α-D-Man/ConA	(Mahon et al., 2013)
Lac; β-CD	12.1±1 nm	Covalent (-SH)		PNA; human galectin-3	UV-Vis	2 µM	Lac/PNA	(Aykanç et al., 2014)
α-D-Man		Covalent (-SH)		ConA; SNA; PNA; UEA; WGA	QCM	0.5-17.5 nM	α-D-Man/ConA	(Zeng et al., 2014)

Carbohydrate	Particle size/type	Coupling method (Functional group)	Carbohydrate density	Protein types	Detection methods/assays	Detection range/limit	Selectivity	References
$\beta$ -D-Gal	10-100 nm	Covalent (-NH <sub>2</sub> )		PNA; WGA; ConA; LCA120; BSA; pepsin	UV-Vis	0.01-0.05 $\mu$ M; 3.5 nM	$\beta$ -D-Gal/PNA	(Hu et al., 2015)
Lac; $\alpha$ -D-Man; $\beta$ -D-GlcNAc	15 nm	Covalent (-SH)		RCA120; ConA; WGA	UV-Vis; DLS	0.5-10 nM; 300 pM	Lac/RCA120; $\alpha$ -D-Man/ConA; $\beta$ -D-GlcNAc/WGA	(Huang et al., 2015)
Carbon glyconanomaterials								
$\alpha$ -D-Man; Dextran	N/A (Fullerene)	Covalent (-NH <sub>2</sub> )		ConA	SPR	0.13 mM	$\alpha$ -D-Man/ConA	(Kato et al., 2001)
$\alpha$ -D-Gal; $\beta$ -D-Gal	65-70 nm (SWNTs)	Non-covalent (-lipid)	10-25 nm thickness	HPA	Fluorescence	100 $\mu$ g/mL	$\alpha$ -D-Gal/HPA	(Chen et al., 2004)
Lac	0.8-1.4 nm (SWNTs)	Covalent (native)		RCA120; ConA; WGA	Confocal microscopy	0.28 mg/mL	Lac/RCA120	(Hasegawa et al., 2004)
$\alpha$ -D-Man; Lac; $\beta$ -D-Gal	5-10 nm (SWNTs)	Non-covalent (-pyrene)		ConA; PNA; PTA	Fluorescence	100 $\mu$ g/mL	$\alpha$ -D-Man/ConA; Lac/PNA; $\beta$ -D-Gal/PTA	(Yu et al., 2008)
D-GlcNAc; $\beta$ -D-Glc; $\alpha$ -D-Man	10-30 nm (SWNTs)	Non-covalent (-pyrene)		HPA; ConA	Fluorescence	5 mM	$\alpha$ -D-Man/ConA	(Sudhija et al., 2009)
Maltose	1.12 $\pm$ 0.04 nm (Graphene)	Non-covalent (-pyrene)		ConA; BSA	Fluorescence	0.02-1 mM; 0.8 nM	Maltose/ConA	(Chen et al., 2011)
Lac	20-50 nm (MWNTs)	Non-covalent (-lipid)		BSA	Circular dichroism	0.04 mg/mL	Lac/BSA	(Feng et al., 2011)
$\alpha$ -D-Man; $\alpha$ -D-Glc	N/A (Fullerene)	Covalent (-NH <sub>2</sub> )	24/particle	ConA	ITC	0.017-0.055 mM	$\alpha$ -D-Man/ConA	(Sánchez-Navarro et al., 2011)
$\beta$ -D-Gal; $\alpha$ -L-Fuc; $\alpha$ -D-Man	0.73-10.4 nm (Graphene); 3.5-23.4 nm (SWNTs)	Non-covalent (-pyrene)		PA-IL; PA-III; ConA	Electrolyte-gated FET; ITC	2 $\mu$ M	$\beta$ -D-Gal/PA-IL; $\alpha$ -L-Fuc/PA-III; $\alpha$ -D-Man/ConA	(Chen et al., 2012)
D-Glc	15 $\pm$ 3 nm (MWNTs)	Covalent (-CHO)		ConA	Electrochemical impedance spectroscopy	3.3 pM-9.3 nM; 1.0 pM	D-Glc/ConA	(Hu et al., 2012)
$\alpha$ -D-Man	1.2-2.5 nm (SWNTs)	Non-covalent (-lipid)		ConA; WGA	Confocal microscopy; SPR	$\sim$ 6000 RU	$\alpha$ -D-Man/ConA	(Murthy et al., 2012)
$\alpha$ -D-Man	4-8 nm (Graphene); 3.5 nm (SWNTs)	Covalent (-NH <sub>2</sub> )	6 wt%; 35 wt%	ConA; BSA	UV-Vis	0.2 mg/mL	$\alpha$ -D-Man/ConA	(Ragoussi et al., 2013)
Polymer glyconanomaterials								
$\alpha$ -D-Man	N/A (Acrylamide)	Covalent (-acrylic amide)	5% of monomers	ConA	QCM; SPR	$5 \times 10^{-10}$ M	$\alpha$ -D-Man/ConA	(Yu et al., 2007)
Neu5Ac $\alpha$ 2-6 Gal $\beta$ 1-4Glc	N/A (Acrylamide)	Covalent (-OCN)		MAA; SNA; PNA	SPR; microarray	0.075-7.5 nM; $10^{-6}$ M	$\beta$ -D-Gal/PNA	(Narla and Sun, 2012)
$\alpha$ -D-Man	7-10 nm (Acrylamide)	Covalent (-NH <sub>2</sub> )	1-3/chain	ConA	SPR; ITC	8 nM	$\alpha$ -D-Man/ConA	(Ponader et al., 2012)
$\alpha$ -D-Man	2.7 nm (Acrylamide)	Covalent (-acrylic amide)	36, 4.8 $\mu$ mol/m <sup>2</sup>	ConA; BSA	QCM	5 mg/L	$\alpha$ -D-Man/ConA	(Seto et al., 2012)
$\alpha$ -D-Man; $\beta$ -D-Gal; $\beta$ -D-GlcNAc	N/A (Styrene)	Covalent (-NH <sub>2</sub> )		ConA; PNA; WGA	QCM	0.2 mg/mL	$\alpha$ -D-Man/ConA; $\beta$ -D-Gal/PNA; $\beta$ -D-GlcNAc/WGA	(Baradel et al., 2013)
$\alpha$ -D-Man	50 nm (Methacrylate)	Covalent (-acrylic amide)	39 nm	ConA; BSA	QCM; SPR	$10^{-9}$ - $10^{-6}$ M; 1 ng/mm <sup>2</sup>	$\alpha$ -D-Man/ConA	(Seto et al., 2014)
$\alpha$ -D-Man; Lac	N/A (Acrylamide)	Covalent (-acrylic amide)	5.3-20.4 %/polymer	ConA; PNA	QCM; UV-Vis	200 nM	$\alpha$ -D-Man/ConA; Lac/PNA	(Tanaka et al., 2014a)
Lac; Neu5Ac $\alpha$ 2-6 Gal $\beta$ 1-4Glc; N-glycan	N/A (Acrylamide)	Covalent (-NH <sub>2</sub> )	7.2-7.7 %/polymer	PNA; BSA; SSA	QCM	20 nM	Lac/PNA; Neu5Ac $\alpha$ 2-6Gal $\beta$ 1-4Glc/BSA; N-glycan/SSA	(Tanaka et al., 2014b)
$\alpha$ -D-Man	80-200 nm (Methacrylate)	Covalent (-acrylic amide)		ConA; BSA	QCM; SPR; UV-Vis	$10^{-5}$ - $10^{-1}$ g/L; 6.0 ng/mL	$\alpha$ -D-Man/ConA	(Tanaka et al., 2014)
Lac; $\beta$ -D-Glc; D-Gal	N/A (Methacrylate)	Covalent (-acrylic amide)		RCA120	QCM	10 $\mu$ g/mL	Lac/RCA120	(Wang et al., 2014)
$\alpha$ -D-Man; $\beta$ -D-Gal	250 $\times$ 2 nm	Covalent (-NH <sub>2</sub> )		ConA; SBA	fluorescence		$\alpha$ -D-Man/ConA; $\beta$ -D-Gal/SBA	(Zhou et al., 2014)
$\alpha$ -D-Man; $\beta$ -D-Gal	265 $\times$ 5 nm	Covalent (-NH <sub>2</sub> )	0.6 nmol/g	ConA; RCA120	fluorescence		$\alpha$ -D-Man/ConA; $\beta$ -D-Gal/RCA120	(Zhou et al., 2015a)
Dendrimer glyconanomaterials								
$\alpha$ -D-Man; $\beta$ -D-Glc	N/A (CD)	Covalent (-SH)	7-14/compound	ConA	ITC	0.07-0.4 $\mu$ M	$\alpha$ -D-Man/ConA	(Ortega-Caballero et al., 2001)

Carbohydrate	Particle size/type	Coupling method (Functional group)	Carbohydrate density	Protein types	Detection methods/assay	Detection range/limit	Selectivity	References
D-GlcNAc	N/A (CD)	Covalent (-SH)	7/compound	E-selectin; BSA	SPR	0.9 $\mu$ M	D-GlcNAc/E-selectin	(Funike et al., 2005)
D-Glc	4.5 nm (Amidoamine)	Covalent (-alkene)	10/compound	ConA	Fluorescence	0-33 mM; 5.5 mM	D-Glc/ConA	(Ibey et al., 2005)
Lac	16 nm	Covalent (-SH)	60-1970/particle	Cholera toxin	UV-Vis	54 nM (3 $\mu$ g/mL)	Lac/Cholera toxin	(Schofield et al., 2007)
Globotriose	4-20 nm	Covalent (-SH)	6-18/compound	Shiga-like Toxin	SPR; UV-Vis	1 mg/mL	Globotriose/Shiga-like Toxin	(Chen et al., 2008)
$\alpha$ -D-Man; $\beta$ -D-Gal; $\beta$ -D-Glc	N/A (Amidoamine)	Covalent (-NH <sub>2</sub> )	6-18/compound	ConA	Turbidimetry	1 mg/mL	$\alpha$ -D-Man/ConA	(Kikkeri et al., 2008)
Lac	9.0-18.1 nm (silole-core carboxylate)	Covalent (-SAO)	6/compound	PNA; WGA	Fluorescence	20 $\mu$ M	Lac/PNA	(Hauano et al., 2009)
$\alpha$ -D-Man	N/A (Ruthenium-Amidoamine)	Covalent (-NH <sub>2</sub> )	6-18/compound	GNA; ConA	Fluorescence	25-347 nM; 25 nM	$\alpha$ -D-Man/GNA	(Kikkeri et al., 2009a)
$\alpha$ -D-Man	0.7-1.6 nm (Gallic acid-triethylene glycol)	Covalent (-N <sub>3</sub> )	3-27/compound	ConA	SPR	12-24 nM	$\alpha$ -D-Man/ConA	(Munoz et al., 2009)
$\alpha$ -D-Man	N/A (Amidoamine)	Covalent (-NCS)	16-172/compound	ConA	Fluorescence	100 $\mu$ g/mL	$\alpha$ -D-Man/ConA	(Schlick et al., 2009)
Lac; Neu5Ac2-6 Gal $\beta$ -4Glc	N/A (Tetraphenylethylene)	Covalent (-N <sub>3</sub> )	4/compound	RCA120; SSA	Fluorescence	20 $\mu$ M	Lac/RCA120	(Kato et al., 2010)
$\alpha$ -D-Man; $\beta$ -D-Gal	N/A (Ruthenium-Amidoamine)	Covalent (-NH <sub>2</sub> )	2-18/compound	ConA; Asialoglycoprotein; GNA	Fluorescence	25-38 nM; 2.5 nM	$\alpha$ -D-Man/ConA	(Kikkeri et al., 2010a)
$\alpha$ -D-Man; $\beta$ -D-Gal; D-Glc; maltose	N/A (Ruthenium-Amidoamine)	Covalent (-NH <sub>2</sub> )	6-18/compound	ConA	Microarray	2.5 nM	$\alpha$ -D-Man/ConA	(Kikkeri et al., 2010b)
D-Glc	N/A (Ethylene glycol)	Covalent (-dichlorotriazine)	12/compound	ConA	Confocal microscopy; fluorescence	50-200 mg/dL	D-Glc/ConA	(Cummin et al., 2011)
$\alpha$ -D-Man	N/A (Ruthenium-CD)	Non-covalent (host-guest interaction)	14-56/compound	ConA (high density); ConA (low density)	SPR	0.138-4.573 $\mu$ M; 0.1380 $\mu$ M	$\alpha$ -D-Man/ConA (high density)	(Grinstein et al., 2011)
$\alpha$ -D-Man	2 nm (Amidoamine)	Covalent (-NCS)	10/compound	ConA; WGA	Fluorescence	1 mg/mL	$\alpha$ -D-Man/ConA	(Bogdan et al., 2012)
$\alpha$ -D-Man	N/A (Amidoamine)	Covalent (-alkyne)	4-16/compound	ConA; BSA	ITC; DPV	10 $\mu$ M	$\alpha$ -D-Man/ConA	(Martos-Maldonado et al., 2013)
$\alpha$ -D-Man	N/A (Ether)	Covalent (-N <sub>3</sub> )	9-81/compound	ConA	SPR	1 pg/mm <sup>2</sup>	$\alpha$ -D-Man/ConA	(Munoz et al., 2013)

Abbreviations: Carbohydrates Ara, arabinose; CD, cyclodextrin; Dex, dextran; Fuc, fucose; Gal, galactose; Glc, glucose; GlcNAc, N-acetyl-D-glucosamine; Lac, lactose; Man, mannose; Mal, maltose; Suc, sucrose. Proteins BSA, bovine serum albumin; BS-I, bandeiraea simplicifolia lectin I; ConA, Concanavalin A; GNA, Galanthus nivalis agglutinin; GS-II, Griffonia simplicifolia II; HPA, Helix pomatia agglutinin; MAA, Maackia amurensis agglutinin; MAL, Maackia amurensis; PA-IL, Pseudomonas aeruginosa I lectin; PA-III, Pseudomonas aeruginosa II lectin; PNA, peanut agglutinin; PSA, Pisum sativum agglutinin; PTA, Psophocarpus tetragonolobus agglutinin; RCA120, Ricinus communis agglutinin; SBA, soybean agglutinin; SNA, Sambucus nigra agglutinin; SSA, Sambucus sieboldiana agglutinin; UEA, Ulex europaeus agglutinin; VAA, Viscum album agglutinin; WGA, wheat germ agglutinin. Instruments DLS, dynamic light scattering; DPV, differential pulse voltammetry; ITC, isothermal titration calorimetry; QCM, quartz crystal microbalance; SPR, surface plasmon resonance spectroscopy.

Table 2

Summary of sensing and imaging microbes and cells in vitro using glyconanomaterials.

Carbohydrate	Particle size/type	Coupling method (Functional group)	Carbohydrate density	Microbe/cell types	Detection methods/assay	Detection limit (mL)	Selectivity	References
Gold glyconanomaterials								
Lac; $\beta$ -D-Glc; maltose	1.6-2.1 nm	Covalent (-SH)		hTERT-B1 cells	Fluorescence microscopy; optical microscopy	$1 \times 10^4$	Lac/hTERT-B1 cell; $\beta$ -D-Glc/hTERT-B1 cell	(De la Fuente et al., 2007)
Dextran	$22 \pm 3$ nm	One-pot (native)		E. coli 8739	UV-Vis	$1 \times 10^6$	Dextran/E. coli 8739	(Nath et al., 2008)
$\alpha$ -D-Man	2.9 nm	Covalent (-SH)		E. coli K12	Fluorescence	$7.2 \times 10^5$	$\alpha$ -D-Man/E. coli K12	(Huang et al., 2009)
$\beta$ -D-Gal	4 nm	Covalent (-SH)	$\sim 65$ /particle	Vero cells	Luminometry	$1 \times 10^4$	$\beta$ -D-Gal/Vero cell	(Kulkarni et al., 2010)
Polysialic acid; D-Man; D-Gal	13 nm	Covalent (native)	55/particle	BGC cells	Confocal microscopy; fluorescence	210	Polysialic acid/BGC cell	(Han et al., 2011b)
D-Glc	5 nm	Covalent (-SH)		KB cells; A549 cells	Flow cytometry; confocal microscopy	$2 \times 10^4$	Glc/KB cell	(Li et al., 2011)
Lac	200 nm	Covalent (-SH)		C33 cells	Confocal microscopy		Lac/C33 cell	(Giallo et al., 2012)
D-Man		Covalent (native)		E. coli ORN178; E. coli ORN208; E. coli 13762	Fluorescence microscopy		Man/E. coli ORN178	(Vedantam et al., 2012)
$\alpha$ -Neu5Ac	$16.4 \pm 1.6$ nm	Covalent (-SH)		influenza virus H3N2; H5N1	UV-Vis	$2.55 \mu\text{g/mL}$	$\alpha$ -Neu5Ac/H3N2	(Marin et al., 2013)
D-Gal; D-Glc; D-Gal	3 nm	Covalent (-SH)		Human monocyte-derived dendritic cells	Flow cytometry	$1 \times 10^6$	D-Gal/dendritic cell	(Chiudo et al., 2014)
$\beta$ -D-Glc	1.5 nm	Covalent (-SH)		HepG2 cells	Confocal microscopy; fluorescence correlation spectroscopy	$1 \times 10^5$	$\beta$ -D-Glc/HepG2 cell	(Murray et al., 2014)
Magnetic glyconanomaterials								
Vancomycin	3-4 nm	Covalent (-NH <sub>2</sub> )		Staphylococcus aureus; S. epidermidis	Optical microscopy	4	Vancomycin/Both	(Gu et al., 2003a)
Vancomycin	4 nm	Covalent (-NH <sub>2</sub> )		E. coli	Optical microscopy	15	Vancomycin/E. coli	(Gu et al., 2003b)
$\alpha$ -D-Man; $\beta$ -D-Gal	10-20 nm	Covalent (-N <sub>3</sub> -NH <sub>2</sub> )	300/particle	E. coli ORN178; E. coli ORN208	Fluorescent microscopy	$10^4$	$\alpha$ -D-Man/E. coli ORN178	(El-Boubbou et al., 2007)
$\alpha$ -D-Man	1.6-6.6 nm	Covalent (native)	30 wt%	rMSCs	MRI; Prussian blue staining	31100	$\alpha$ -D-Man/rMSCs	(Horak et al., 2007)
Hyaluronic acid	40-50 nm	Non-covalent (native)		HEK293 cells; A549 cells	Fluorescence microscopy	40000	Hyaluronic acid/Both	(Kumar et al., 2007)
$\beta$ -D-Gal	$\sim 10$ nm	Covalent (-amphiphile)		Hepatocytes	Confocal microscopy	$10^5$	$\beta$ -D-Gal/Hepatocytes	(Yoo et al., 2007)
$\alpha$ -D-Man; Lac; $\alpha$ -Neu5Ac	2-3 $\mu\text{m}$	Covalent (-biotin)		E. coli ORN178; E. coli ORN208; J96-F1E; PT22 Tox; B41; CF1073	Optical microscopy	$10^5$	$\alpha$ -D-Man/E. coli ORN178	(Hatch et al., 2008)
Vancomycin	10 nm	Covalent (-NH <sub>2</sub> ) e	9-12/particle	E. coli; E. faecalis; S. epidermidis; S. aureus	Microagglutination		Vancomycin/All	(Kell et al., 2008)
Hyaluronic acid	$12 \pm 0.1$ nm	Non-covalent (native)		HCT116 cells; NIH3T3 cells	MRI	$2 \times 10^5$	Hyaluronic acid/Both	(Lee et al., 2008)
$\alpha$ -D-Man	$\sim 10$ nm	Covalent (native)		Macrophage cells	MRI		$\alpha$ -D-Man/Macrophage cells	(Yoo et al., 2008)
Chitosan	6-10 nm	Covalent (-COOH)		hMSCs	MRI; Prussian blue staining	40	Chitosan/hMSCs	(Shi et al., 2009)
$\alpha$ -D-Man; $\beta$ -D-Gal; $\beta$ -L-Fuc; $\beta$ -Neu5Ac; $\beta$ -D-GlcNAc	6 nm	Covalent (-N <sub>3</sub> -NH <sub>2</sub> )	8 wt%	184B5; A498; A549; HT29; SKOV-3; B16-F10; B16-F1; MCF-7; TA3-HA; TA3-ST cells	MRI; Prussian blue staining	$10^5$	$\beta$ -Fuc/A549&HT29; $\alpha$ -D-Man/184B 5&MCF-7; $\beta$ -Gal/B16-F 10&MCF-7; $\beta$ -Neu5Ac/All; $\beta$ -D-GlcNAc/S KOV-3	(El-Boubbou et al., 2010)
Hyaluronic acid	6 nm	Covalent (native)		THP-1 cells; EA.hy926 cells; LNCaP cells	MRI; Prussian blue staining; flow cytometry; confocal microscopy	$4 \times 10^5$	Hyaluronic acid/THP-1 cell	(Kamat et al., 2010)

Carbohydrate	Particle size/type	Coupling method (Functional group)	Carbohydrate density	Microbe/cell types	Detection methods/assay	Detection limit (mL)	Selectivity	References
Gal(1-4Gal	250 nm	Covalent (-N <sub>3</sub> )		Streptococcus suis bacteria	Luminescence	10 <sup>5</sup>	Gal(1-4Gal/Streptococcus suis	(Pera et al., 2010)
Lac	9 nm	Covalent (-SH)	~60/particle	Peripheral blood mononuclear cells	MRI; fluorescence microscopy	10 <sup>5</sup>	Lac/mononuclear cell	(Gallo et al., 2011)
Lac	6 nm	Covalent (-SH)		C33 cells; Raji cells	MRI; flow cytometry; fluorescence microscopy	5 × 10 <sup>3</sup>	Lac/C33 cell	(García et al., 2011)
β-D-Gal	14 nm	Covalent (-SH)		A549 cells	Epifluorescence microscopy; confocal microscopy	10 <sup>4</sup>	β-D-Gal/A549 cell	(Plaiff et al., 2011)
Hyaluronic acid	5 nm	Covalent (native)	44 wt%	SKOV-3 cells	MRI; confocal microscopy	2 × 10 <sup>5</sup>	Hyaluronic acid/SKOV-3 cell	(El-Dakdouki et al., 2012)
Carbon glyconanomaterials								
β-D-Gal; α-D-Man	~20 nm (SWNTs)	Covalent (-NH <sub>2</sub> )		E. coli O157:H7	Optical microscopy		β-D-Gal/E. coli O157:H7	(Gu et al., 2005)
α-D-Gal; β-D-Gal	65-70 nm (SWNTs)	Non-covalent (-lipid)	10-25 nm thickness	CHO cells	Fluorescence microscopy; flow cytometry		α-D-Gal/CHO cell	(Chen et al., 2006)
D-GlcN	20 nm (SWNTs)	Covalent (-NH <sub>2</sub> )		3T3 fibroblasts cells	Optical microscopy	10 <sup>4</sup>	D-GlcN/3T3 cell	(Nimmagadda et al., 2006)
β-D-Gal; α-D-Man	N/A (SWNTs)	Covalent (-NH <sub>2</sub> )		B. anthracis spores	Optical microscopy		α-D-Man/B. anthracis spores	(Wang et al., 2006)
β-D-Gal; α-D-Man	~20 nm (SWNTs)	Covalent (-NH <sub>2</sub> )	37-45 wt%; 35-47 wt%	E. coli O157:H7; B. subtilis spores	Fluorescence microscopy; optical microscopy	5 × 10 <sup>7</sup>	β-D-Gal/E. coli O157:H7; α-D-Man/B. anthracis spores	(Gu et al., 2008)
α-D-Man; β-D-Gal	5-10 nm (SWNTs)	Non-covalent (-pyrene)		CHO cells	Fluorescence microscopy		α-D-Man/CHO cell	(Wu et al., 2008)
D-GlcNAc; β-D-Glc; α-D-Man	10-30 nm (SWNTs)	Non-covalent (-pyrene)		PC12 cells	Semiconductor device analyzer		D-GlcNAc/PC12 cell	(Sudhya et al., 2009)
D-Man; D-Glc	N/A (Diamond)	Covalent (-alkene/-NH <sub>2</sub> )		E. coli PKL1162	Agglutination-filtration assay	37	D-Man/E. coli PKL1162	(Hartmann et al., 2012)
α-D-Man; β-D-Gal	1 nm (Fullerene)	Covalent (-N <sub>3</sub> )	12-36/particle	Ebola pseudovirus		5000	α-D-Man/Ebola pseudovirus	(Luczkiowiak et al., 2013)
QD glyconanomaterials								
Cellobiose; Lac; Maltose	5 nm (CdSe)	Non-covalent (-amphiphile)		HeLa cells	Fluorescence microscopy		Cellobiose/HeLa cell	(Osaki et al., 2004)
β-D-GlcNAc	5 nm (CdSe/ZnS)	Covalent (-SH)	210/particle	Mouse sperm; pig sperm; sea-urchin sperm	Confocal microscopy; flow cytometry	2.7 × 10 <sup>6</sup>	β-D-GlcNAc/All	(Robinson et al., 2005)
D-GlcNAc; β-D-Gal; α-D-Man	12 nm (CdTe)	Covalent (-SH)		HeLa cells	Confocal microscopy	10 <sup>5</sup>	D-GlcNAc/HeLa cell	(Niikura et al., 2007)
Chitosan	29 nm (InGaP/ZnS)	Covalent (native)		PC12 cells	Flow cytometry; Explore Optix imaging		Chitosan/PC12 cell	(Sandros et al., 2007)
β-D-Gal	5=0.5 nm (CdSe/ZnS)	Covalent (-N <sub>3</sub> )		A549; H467; HeLa; COS-7; CL1-1 cells	Confocal microscopy		β-D-Gal/A549 cell	(Chen et al., 2008)
D-Man	20-30 μm (Qdot@655)	Non-covalent (-PEG)		Macrophage cells	Fluorescence microscopy	1.3 × 10 <sup>5</sup>	D-Man/Macrophage cell	(Higuchi et al., 2008)
Maltotriose; panose; maltose	12 nm (CdTe)	Covalent (-SH)	28/particle	HeLa cells	Confocal microscopy		Maltotriose/HeLa cell	(Niikura et al., 2008)
Hyaluronic acid	5.7 nm (CdSe/CdS/ZnS)	Non-covalent (native)		HeLa cells; Human dermal fibroblast cells	Fluorescence microscopy	10 <sup>4</sup>	Hyaluronic acid/HeLa cell	(Bhang et al., 2009)
β-D-Gal; α-D-Man	15-20 nm (CdSe/ZnS)	Covalent (-COOH)		HepG2 cells	Flow cytometry; fluorescence microscopy		β-D-Gal/HepG2 cell	(Kikkiri et al., 2009b)
α-D-Man	15 nm (CdS)	Covalent (-SH)		E. coli ORN178; E. coli ORN208	Confocal microscopy	10 <sup>4</sup>	α-D-Man/E. coli ORN178	(Mukhopadhyay et al., 2009)
β-D-Gal; β-D-Man; β-D-Glc	2.5 nm (CdTe)	Non-covalent (native)		Saccharomyces cerevisiae; Kluyveromyces fragilis	Epifluorescence microscopy; Optical microscopy		β-D-Gal/Saccharomyces cerevisiae; β-Man/Kluyveromyces fragilis	(Coulon et al., 2010)
Hyaluronic acid	42.3 nm (Qdot@800)	Covalent (-NH <sub>2</sub> )		HepG2; HSC-T6; FL83B cells	Flow cytometry; confocal microscopy; immunofluorescence staining	3 × 10 <sup>4</sup>	Hyaluronic acid/HepG2	(Kim et al., 2010)
Lac	4.5 ± 0.5 nm (CdSeS/ZnS)	Covalent (-SH)	134-140/particle	HUVEC cells	SPR; fluorescence microscopy		Lac/HUVEC cell	(Yang et al., 2010a)
β-D-Gal; β-Lac	4.5 ± 0.5 nm (CdSeS/ZnS)	Covalent (-SH)	35.3-48.7 wt%	HepG2 cells	Flow cytometry; fluorescence microscopy	10 <sup>5</sup>	β-D-Gal/HepG2 cell	(Yang et al., 2010b)

Carbohydrate	Particle size/type	Compling method (Functional group)	Carbohydrate density	Microbe/cell types	Detection methods/assay	Detection limit (/mL)	Selectivity	References
Mannan	3.1 nm (CdS)	Covalent (-NH <sub>2</sub> )	2-10 wt%	BGC cells	Flow cytometry	1.2 × 10 <sup>3</sup>	Mannan/BGC cell	(Han et al., 2011a)
β-D-Gal	4 nm (CdS)	Covalent (-NH <sub>2</sub> )		HepG2; MCF-7 cells	Fluorescence; confocal microscopy		β-D-Gal/HepG2 cell	(Cai et al., 2012)
Silica glyconanomaterials								
β-D-Gal	60±5 nm (solid)	Covalent (-COOH)	5.045 wt%	Liver cancer cells; MCF-7 cells; blood cells	Fluorescence microscopy; flow cytometry		β-D-Gal/Liver cancer cell	(Peng et al., 2007)
α-D-Man	~100 nm (solid and mesoporous)	Covalent (-Diethyl squarate)	0.18 mmol/g	MDA-MB-231 cells	Confocal microscopy		α-D-Man/MDA-MB-231 cell	(Hocine et al., 2010)
α-D-Man	118 nm (mesoporous)	Covalent (-Diethyl squarate)		MCF-7; MDA-MB-231; HCT-116 cells	Optical microscopy		α-D-Man/MCF-7 & MDA-MB-231 cell	(Gary-Bobo et al., 2011)
D-Gal; D-Glc	54-54 nm (solid)	Covalent (-alkynyl)	-0.6 μmol/mg	Oligodendrocytes	Confocal microscopy		D-Gal/Oligodendrocytes	(Zhao et al., 2012)
β-D-Man	~6 nm (solid)	Covalent (-COOH)		MCF-7 cells	Fluorescence microscopy		β-D-Man/MCF-7 cell	(Ahire et al., 2013)
D-Maltoheptaose; β-CD; D-Man	81.2 ± 7.3 nm (solid)	Photocoupling (native)	11517-68623/particle	E. coli	Confocal microscopy		D-Maltoheptaose/E. coli	(Jayawardena et al., 2013a)
α-D-Man	148-161 nm (solid)	Covalent (-Diethyl squarate)	1.95 mmol/g	MDA-MB-231 cells	Confocal microscopy		α-D-Man/MDA-MB-231 cell	(Bernier et al., 2013)
Vancomycin	90 ± 37 nm (mesoporous)	Covalent (-COOH)	50 wt%	S. aureus; RAW 264.7 cells; E. coli	Confocal microscopy	10 <sup>5</sup>	Vancomycin/S. aureus & RAW 264.7 cell	(Qi et al., 2013)
D-Tre; β-CD; D-Glc; D-Maltoheptaose	42.1 ± 1.9 nm (solid)	Photocoupling (native)	7.25-16.0 × 10 <sup>-16</sup> μg/mm <sup>2</sup>	M. smegmatis strain mc <sup>2</sup> 155	Confocal microscopy		D-Tre/M. smegmatis strain mc <sup>2</sup> 155	(Jayawardena et al., 2015)
Dendrimer glyconanomaterials								
Galα1-4Gal	N/A (Benzenedimethanethiol)	Covalent (-NH <sub>2</sub> )	1-4/compound	Streptococcus suis	Hemagglutination	10 <sup>8</sup>	Galα1-4Gal/Streptococcus suis	(Hansen et al., 1997)
α-D-Man	N/A (Amide series)	Covalent (-NH <sub>2</sub> )	2-16/compound	E. coli K12	Hemagglutination	10 <sup>8</sup>	α-D-Man/E. coli K12	(Nagahori et al., 2002)
α-D-Man	N/A (BoltonH30)	Covalent (-NH <sub>2</sub> )	32/compound	Dendritic cells; Ebola virus			α-D-Man/Dendritic cell & Ebola virus	(Lasala et al., 2003)
Galα1-4Gal	N/A (Amidoamine)	Covalent (-COOH)	8/compound	Streptococcus suis	Hemagglutination; SPR		Galα1-4Gal/Streptococcus suis	(Joosten et al., 2004)
D-GlcNAc	N/A (Amidoamine)	Covalent (-NCS)	8/compound	Mononuclear cells	Fluorescence microscopy; confocal microscopy		D-GlcNAc/Mononuclear cells	(Krist et al., 2004)
D-GlcN; glucosamine 6-sulfate	N/A (Amidoamine)	Covalent (native)	14%	Dendritic cells; monocyte-derived macrophages	Trypan blue exclusion; hemagglutination	10 <sup>6</sup>	D-GlcN/Both	(Shaunak et al., 2004)
Galα1-4Gal; D-Man	N/A (Amidoamine)	Covalent (-COOH)	1-8/compound	E. coli HB101; T24 cells	SPR; hemagglutination		Galα1-4Gal/Both	(Salminen et al., 2007)
α-D-Man; mannan	N/A (Tetra-compound)	Covalent (-N3/alkyne)	4/compound	E. coli UT189	Hemagglutination; SPR		α-D-Man/E. coli UT189	(Touaibia et al., 2007)
Galα1-4Gal	N/A (Phenolic acid)	Covalent (-N3)	1-8/compound	Streptococcus suis	Hemagglutination		Galα1-4Gal/Streptococcus suis	(Branderhorst et al., 2008)
D-GlcNAc	N/A (Amidoamine)	Covalent (-NCS)	8/compound	Mononuclear cells	Flow cytometry		D-GlcNAc/Mononuclear cells	(Hulikova et al., 2009)
Neu5Acα2-6Galβ1-4Glc; Lac	N/A (Tetraphenylethylene)	Covalent (-N3)	4/compound	Influenza virus A/WSN/33	Fluorescence	5 × 10 <sup>4</sup>	Neu5Acα2-6Galβ1-4Glc /Influenza virus A/WSN/33	(Kato et al., 2010)
α-D-Man	N/A (Ruthenium-CD)	Non-covalent (host-guest interaction)	14-56/compound	E. coli ORN178; E. coli ORN208	Confocal microscopy		α-D-Man/E. coli ORN178	(Grinstein et al., 2011)
D-GlcNAc	N/A (Amidoamine)	Covalent (-NCS)	8/compound	Mononuclear cells	Flow cytometry	10 <sup>6</sup>	D-GlcNAc/Mononuclear cell	(Hulikova et al., 2011)



Table 3

Tissue- and in vivo- sensing/imaging using gold-, magnetic-, and QD-glyconanomaterials.

Carbohydrate	Particle size/type	Compling method (Functional group)	Carbohydrate density	Animal type	Detection methods/assay	Target	Selectivity	References
Gold glyconanomaterials								
Lac; maltose; $\beta$ -D-Glc	<2 nm	Covalent (-SH)	70/particle	C57BL/6 mice	Histological analysis	Lung tumor	Lac/Lung tumor	(Rojo et al., 2004)
$\beta$ -D-Gal	50-150 nm	Covalent (-SH)	4/nm <sup>2</sup>	C57BL/6 (female)	Instrumental neutron activation technique	Liver	$\beta$ -D-Gal/Liver	(Bergen et al., 2006)
Hyaluronic acid	16 nm	Covalent (-SH)	30.9±1.7/particle	DBA-1J mice; BALB/c nude mice	Near-infrared fluorescent imaging	Amblyotic tumor	Hyaluronic acid/Both	(Lee et al., 2008)
$\beta$ -D-Glc; Lac; $\beta$ -D-Gal	1.9-4.4 nm	Covalent (-SH)	C57BL/6	C57BL/6	MRI	Brain tumor	$\beta$ -D-Glc/Brain tumor	(Marradi et al., 2009)
Heparin; D-Glc	1.4±4 nm	Covalent (-NH <sub>2</sub> )	10.5±1.2 nmol/mg	Chick embryos; C57BL/6 NC1 (male)	Stereomicroscopy	Chorioallantoic membrane	Heparin/Chorioallantoic membrane	(Kemp et al., 2009)
Sialyl Lewis <sup>X</sup>	18 nm	Covalent (-NH <sub>2</sub> )	59-174	C57BL/6 (male)	MRI; Prussian blue staining	Brain; spleen; liver	Sialyl Lewis <sup>X</sup> /All	(Farr et al., 2014)
$\beta$ -D-Glc	1.8-3.2 nm	Covalent (-SH)	59-174	Sprague-Dawley rats (male)	PET/CT	Brain	$\beta$ -D-Glc/Brain	(Friggeri et al., 2014)
Magnetic glyconanomaterials								
$\beta$ -D-Gal	~10 nm	Covalent (-amphiphilic)		Rats (SD, female)	MRI	Liver	$\beta$ -D-Gal/Liver	(Yoo et al., 2007)
Sialyl Lewis <sup>X</sup> ; $\beta$ -D-GlcNAc; LacNAc; Neu5Ac <sub>2</sub> -3Gal $\beta$ -1-4GlcNAc	~1 $\mu$ m	Covalent (-CN)	10 <sup>5</sup> -10 <sup>7</sup> /particle	Wistar rats (male)	MRI	Brain	Sialyl Lewis <sup>X</sup> /Brain	(van Kesteren et al., 2008)
Hyaluronic acid	6 nm	Covalent (native)	43 wt%	C57BL/6 mice	MRI; Prussian blue staining	Liver; kidney	Hyaluronic acid/Both	(El-Dakdouki et al., 2011)
Lac	4 nm	Covalent (-COOH)		FVB mice; C57BL/6 mice	Stereomicroscopy; confocal microscopy; MRI	Brain tumor	Lac/Brain tumor	(Elvira et al., 2012)
$\beta$ -CD	6 nm	Covalent (native)	19 wt%	Atherosclerotic rabbit	Optical microscopy; MRI; Prussian blue staining	Aorta tissues	$\beta$ -CD/Aorta tissues	(Li et al., 2012)
Neu5Ac	5 nm	Covalent (-COOH)	4 wt%	C57BL/6 mice	MRI; Prussian blue staining	Brain	Neu5Ac/Brain	(Koyoundjian et al., 2013)
Hyaluronic acid	6 nm	Covalent (native)	46 wt%	Atherosclerotic rabbit	MRI; optical microscopy; Prussian blue staining	Aorta tissues	Hyaluronic acid/Aorta tissues	(El-Dakdouki et al., 2014)
Lac	4 nm	Covalent (-COOH)		Mice	MRI; flow cytometry	Brain tumor	Lac/Brain tumor	(Elvira et al., 2015)
QD glyconanomaterials								
Chitosan	29 nm (InGaP/ZnS)	Covalent (native)		Mice	Flow cytometry; Near-infrared fluorescent imaging	Brain	Chitosan/Brain	(Sandros et al., 2007)
Hyaluronic acid	5.7 nm (CdSe/CdS/ZnS)	Non-covalent (native)		Nude mice	Fluorescence microscopy	Ear	Hyaluronic acid/Ear	(Bhang et al., 2009)
$\beta$ -D-Gal; $\alpha$ -D-Man	15-20 nm (CdSe/ZnS)	Covalent (-COOH)		C57BL/6 mice (female)	Flow cytometry; fluorescence microscopy	Liver	$\beta$ -D-Gal/Liver	(Kikkeri et al., 2009b)
Hyaluronic acid	42.5 nm (Qdot@800)	Covalent (-NH <sub>2</sub> )		Balb/c mice (female)	Flow cytometry; Confocal microscopy; luminescent imaging	Liver; Spleen; kidney	Hyaluronic acid/Liver	(Kim et al., 2010)
$\alpha$ -Neu5Ac; Lac; Neu5Ac <sub>2</sub> -3Gal $\beta$ -1-4GlcNAc	5.8-9.3 nm (CdSe/ZnS)	Covalent (-SH)		Mice	Near-infrared fluorescent imaging	Liver; brain; heart; stomach; spleen; kidney; bladder	Neu5Ac <sub>2</sub> -3Gal $\beta$ -1-4GlcNAc/Liver	(Ohyunagi et al., 2011)